 ,run_idx,response_id,model,response_text,input_tokens_api,output_tokens_api,total_tokens_api,input_tokens_tiktoken,output_tokens_tiktoken,est_cost_usd
2025-12-13T17:42:41,0,resp_028080f3430d725600693d27016100819bab707590b6dbf18a,gpt-5.2,"[Origin Task]:
A U.S.-based manufacturing company with 1,200 employees is considering adding a voluntary GLP‑1 weight‑loss medication benefit to its self‑insured health plan after seeing rising rates of obesity‑related absenteeism and short‑term disability claims; however, leadership is concerned about regulatory compliance and clinical safety for workers in safety‑sensitive roles (forklift operators, machine operators). Using applicable U.S. employment/benefits rules (e.g., ERISA plan design requirements, ADA/GINA nondiscrimination and reasonable‑accommodation constraints, and HIPAA privacy limits on collecting health data), assess what the company is legally allowed to require or restrict (e.g., medical clearance, fitness‑for‑duty, disclosure of side effects) and what must remain strictly voluntary. Incorporate medical considerations (contraindications, common adverse effects like hypoglycemia risk when combined with other drugs, nausea/dehydration, and any implications for operating heavy machinery) to propose clinically appropriate eligibility and monitoring guardrails. Quantitatively model the first‑year budget impact and ROI under three uptake scenarios using provided assumptions: drug cost $950/member/month, average eligible population 420 employees, expected uptake 8%/15%/25%, average weight loss reduces obesity‑related claims by 6% per 5% body‑weight reduction, baseline obesity‑related annual claims $3.6M, expected average weight loss 7% among adherent users with 65% adherence at 12 months, and program admin cost $180,000/year. Deliver a recommendation on whether to implement the benefit and, if so, specify compliant plan terms and a go/no‑go threshold based on net cost and safety risk tolerance.",232,356,588,226,352,0.00539
2025-12-13T17:42:48,1,resp_084c667edaaa98d200693d27090ee08197a2d38c54739282f5,gpt-5.2,"[Origin Task]:  
A mid-sized U.S. public school district is considering installing upper-room UV-C air disinfection in 40 classrooms to reduce influenza and COVID-19 transmission, but the teachers’ union and parents are concerned about eye/skin safety, medical risks for students with photosensitivity disorders, and whether the district may legally rely on health screening disclosures. Using applicable U.S. regulatory requirements and standards (e.g., OSHA workplace safety obligations, ADA accommodations, FERPA/HIPAA boundaries for student/staff health information, and state procurement/public-meeting rules), evaluate what the district can and cannot require or collect, and what documentation/training is needed to implement the technology. Quantitatively compare (with transparent assumptions) the expected reduction in absenteeism and healthcare-related costs versus capital/maintenance costs and liability risk, including dose/exposure calculations to confirm UV-C levels remain within recognized safety limits for occupied spaces. Based on this combined legal, medical, and quantitative analysis, deliver a recommendation on whether to proceed now, proceed with conditions (and what conditions), or postpone, and specify the policy language the superintendent should present for board approval.",232,234,466,226,230,0.003682
2025-12-13T17:42:56,2,resp_06dca3d293edec7100693d27101d2c819a93a818e16514bbea,gpt-5.2,"[Origin Task]:  
A mid-sized U.S. school district is considering a policy that would require all middle-school students to receive an mRNA COVID-19 booster before participating in indoor sports, while offering on-site vaccination clinics staffed by a contracted medical group and storing limited health information in the district’s student information system. Using current medical guidance on booster effectiveness and adverse-event rates by age/sex, applicable legal constraints (e.g., parental consent, medical/religious exemptions, HIPAA vs. FERPA handling of health data, and anti-discrimination requirements for students with disabilities), and a quantitative cost–benefit and risk analysis (expected prevented hospitalizations/absences vs. expected adverse events, staffing and clinic costs, and potential liability exposure), determine whether the district should adopt the mandate or choose an alternative (e.g., opt-in program with testing). Assume a 12,000-student district with 4,500 middle-schoolers, 62% already boosted, two indoor sports seasons, and a $350,000 annual budget cap for mitigation. Deliver a board-ready recommendation that specifies the chosen policy, required consent/exemption workflow, minimum necessary data practices, and the quantitative justification under the budget cap.",232,249,481,226,245,0.003892
2025-12-13T17:43:02,3,resp_0b71a91a24a4e1e100693d2716587481999e854c9fc751c5d3,gpt-5.2,"[Origin Task]:
A mid-sized U.S. public school district is considering deploying an AI-enabled smartphone app for high-school athletes that flags possible concussion risk using symptom checklists and phone-based balance tests, then automatically messages parents, coaches, and a contracted telehealth clinician when risk exceeds a threshold. The district must decide whether the program can be launched this semester while complying with applicable federal and state requirements (including student privacy/education records rules, health information/privacy obligations, informed consent for minors, and mandated return-to-play and reporting rules) and while minimizing medical risk from false negatives/positives. Using last year’s sports participation counts and concussion incidence rates provided by the district, estimate expected flagged cases under two alternative alert thresholds, quantify staffing capacity needed for clinician follow-ups within 24 hours, and model cost impacts (app licensing, clinician time, avoided ER visits) under each threshold. Recommend whether to proceed and, if so, specify the legally compliant consent/notification approach and the threshold choice that best balances safety, privacy compliance, and budget.",232,213,445,226,209,0.003388
2025-12-13T17:43:08,4,resp_06b6044995dff60d00693d271d0b4c8198a9805e19de53b387,gpt-5.2,"[Origin Task]:
A U.S. county health department is considering partnering with a telehealth vendor to launch a 12‑month remote hypertension program for 2,500 Medicaid adults using connected blood‑pressure cuffs, pharmacist-led medication titration under collaborative practice agreements, and SMS coaching, with data flowing into the department’s analytics platform. The department must ensure the program’s clinical protocol meets accepted standards of care and patient-safety requirements (e.g., escalation rules for hypertensive urgency, contraindications, adverse-event reporting), while also complying with applicable privacy and security laws and regulations (HIPAA, state medical-licensure/telemedicine rules, and Medicaid billing/consent requirements) given that the vendor will subcontract a cloud provider and call center. The finance team needs a quantitative projection comparing program costs (devices, staffing, vendor fees, training, and cybersecurity controls) against expected savings from reduced ER visits and strokes, using baseline utilization rates, anticipated adherence, and published effect sizes to estimate avoided events and ROI under best/base/worst scenarios. Create a go/no-go recommendation that specifies whether to proceed and under what contractual, clinical, and compliance conditions, including the maximum per-member-per-month price the department should agree to so the program remains cost-effective while meeting legal and medical obligations.",232,261,493,226,257,0.00406
2025-12-13T17:43:15,5,resp_0e4e68dd5b7f69f900693d27237454819ab9bda95c4374156f,gpt-5.2,"[Origin Task]:
A U.S. manufacturing company with 2,400 employees (40% in California, 60% in Ohio) is considering launching an on-site pharmacy program that dispenses naloxone and certain chronic medications, while also offering optional biometric screenings and a medication-adherence incentive of up to $600/year credited to employees’ health-plan premiums. After two opioid-related overdoses occurred in the last year, leadership wants to reduce mortality risk and absenteeism but must ensure the program complies with HIPAA/privacy rules, state pharmacy and naloxone access laws, and nondiscrimination/wellness-incentive limits under federal benefits/employment regulations. Using the company’s last 12 months of claims and attendance data (assume 18 overdoses requiring ER care, average ER cost $3,200; 6 inpatient admissions, average $18,000; 9,600 opioid prescriptions filled; baseline absenteeism 7.2 days/employee-year; average loaded labor cost $310/day) and a proposed vendor bid ($420,000 fixed annual fee plus $28 per participating employee per month, expected 35% participation), estimate the net financial impact over one year under conservative and optimistic effectiveness assumptions and identify the legally required safeguards (consent, data handling, incentive design, and dispensing protocols) needed to implement the program in both states. Provide a recommendation on whether to proceed, what program design to choose, and what compliance conditions must be met before rollout.",232,302,534,226,298,0.004634
2025-12-13T17:43:22,6,resp_052ea5e70405512100693d272aca5c819a9775a9e7dddc94a5,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is considering deploying an AI-powered discharge planning tool that predicts 30-day readmission risk for Medicare patients and automatically recommends post-acute services (home health vs. skilled nursing) and medication changes, using EHR data and a vendor-hosted cloud model. After a pilot, the system observed a 12% relative reduction in readmissions but also a statistically significant increase in adverse drug events among patients with chronic kidney disease, and the vendor proposes expanding to all campuses while charging per avoided readmission under a shared-savings contract. The hospital must decide whether and how to proceed while complying with HIPAA and state medical privacy laws, FDA/FTC guidance on clinical decision support and marketing claims, Medicare Conditions of Participation, and anti-kickback/Stark implications of the proposed payment model, and it needs a quantitative risk–benefit and financial analysis that incorporates sample sizes, baseline readmission rates, confidence intervals, expected penalty changes under the Hospital Readmissions Reduction Program, and projected costs of additional pharmacist review to mitigate kidney-related harms. Prepare a recommendation to the board on whether to scale, pause, or redesign the deployment, specifying the contract structure, clinical safety mitigations, data governance controls, and the quantitative thresholds that must be met to justify rollout.",232,265,497,226,261,0.004116
2025-12-13T17:43:29,7,resp_0096f2f949bd82f700693d273125d481939e52ddaecfc138da,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying a generative-AI “wellness chatbot” to screen students (ages 13–18) for depression and suicide risk, and to route high-risk cases to school counselors and a contracted telehealth provider. Using applicable legal/regulatory requirements (e.g., FERPA, COPPA where relevant, state minor-consent and mandatory-reporting laws, and HIPAA boundary issues with the telehealth vendor), clinical safety standards for suicide-risk triage (including when to escalate to emergency services), and quantitative analysis of expected false positives/negatives given proposed screening thresholds and projected prevalence in the district, determine whether the program can be launched as designed or must be modified. Assume the vendor proposes storing chat logs for 24 months to “improve models,” sending weekly risk reports to principals, and offering an opt-out rather than opt-in consent, and the district has budget constraints that cap counselor follow-up capacity at 50 high-risk referrals per week. Provide a go/no-go recommendation with required policy and technical changes (data retention, consent, access controls, escalation pathways, and reporting), justified by a numerical estimate of weekly referral volume versus capacity and the legal/clinical risk tradeoffs.",232,255,487,226,251,0.003976
2025-12-13T17:43:36,8,resp_097d1cc26812c37800693d2738fe808194beb67a58a2b5818b,gpt-5.2,"[Origin Task]:  
A regional hospital system plans to launch an AI-driven “sepsis early warning” program that continuously analyzes EHR data and pushes alerts to clinicians across three states, but it will also share de-identified outcome data with a university partner and a device vendor for model improvement. After a pilot revealed that the alert increases broad-spectrum antibiotic use and ICU transfers, leadership needs an assessment of whether the clinical benefit justifies the risks, including estimating expected changes in sepsis mortality, C. difficile infections, and ICU bed-days under different alert thresholds using the hospital’s baseline rates and projected patient volumes. The program must also be evaluated for legal/regulatory compliance (e.g., HIPAA privacy and de-identification, state health data laws, FDA software-as-a-medical-device considerations, and clinician liability/standard-of-care implications if alerts are ignored or false positives occur). Prepare a board-ready recommendation on whether to proceed, what threshold and governance policies to adopt, and what contractual/data-use terms and patient-notice/consent approach are required before deployment.",232,217,449,226,213,0.003444
2025-12-13T17:43:42,9,resp_0e00029ad4ee1a5700693d273e645481969143e546c312dcf0,gpt-5.2,"[Origin Task]:
A U.S.-based hospital system wants to launch a telehealth weight-management program that prescribes GLP‑1 medications and offers remote monitoring to employees of a self-insured corporate client across California, Texas, and New York, using a third-party app that collects vitals and lifestyle data. After a recent internal audit found gaps in consent language and uncertainty about whether the app vendor is a HIPAA business associate and how state telemedicine and prescribing rules differ, leadership needs to decide whether to proceed, redesign workflows, or pause rollout. Using basic clinical considerations (indications/contraindications, monitoring cadence, and escalation criteria), applicable privacy/consumer health data and telemedicine regulations (HIPAA, state medical board rules, and any relevant state privacy requirements), and quantitative analysis (project expected adverse-event rate, staffing needs, and budget impact under different eligibility thresholds and adherence scenarios), produce a go/no-go recommendation and specify the minimum policy, contract, and clinical protocol changes required to launch within 90 days while keeping legal and patient-safety risk within defined tolerances.",232,222,454,226,218,0.003514
2025-12-13T17:43:47,10,resp_01e107b66d4d288d00693d27441a288196b6d83f686c3fda1d,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is deciding whether to deploy an AI-assisted mental-health screening program for students (ages 12–18) that analyzes short weekly check-in surveys and flags high-risk responses for follow-up by school counselors, with data processed by a third-party vendor and stored in the cloud. The district needs to ensure the program complies with applicable federal and state requirements (including FERPA, HIPAA boundary issues for school-based health services, parental consent/opt-out rules, mandatory reporting obligations, and vendor contracting/security clauses), while also evaluating potential clinical benefits and harms (false positives leading to unnecessary referrals and stigma, false negatives missing suicidal ideation, appropriate escalation pathways, and staffing capacity). Using last year’s counseling records, assume a 3.0% annual prevalence of clinically significant self-harm risk, the model’s estimated sensitivity is 0.82 and specificity is 0.94, and each counselor can handle 18 additional high-risk follow-ups per week at 45 minutes each; quantify expected weekly flagged cases, positive predictive value, and whether counselor capacity is sufficient, then estimate budget impact given $7 per student per month licensing and $65/hour fully-loaded counselor cost. Provide a recommendation on whether and how to proceed (deploy, pilot, or abandon), specifying the minimum policy/consent language and operational safeguards needed to meet legal compliance and acceptable clinical risk thresholds.",232,288,520,226,284,0.004438
2025-12-13T17:43:55,11,resp_03fc257f0de4921400693d274b5e30819891db119fcc7f2354,gpt-5.2,"[Origin Task]:
A U.S.-based school district is considering deploying an AI-assisted mobile clinic program to screen students (ages 6–17) for asthma control and ADHD symptoms, and to offer on-site telehealth follow-ups with prescriptions routed to local pharmacies. The district must decide whether the program can legally operate under HIPAA, FERPA, state minor-consent rules, and telemedicine/prescribing regulations (including controlled-substance constraints for ADHD medications), while ensuring clinical safety protocols for red-flag symptoms and appropriate referral pathways. Using the vendor’s proposed workflow and staffing model, estimate projected annual medical benefits (reduced ER visits and absenteeism) versus costs (staffing, devices, clinician time, insurance billing denials, and potential regulatory noncompliance penalties), and quantify how results change under different parental-consent rates and false-positive screening rates. Provide a go/no-go recommendation and a compliant operating policy (consent, data sharing, retention, emergency escalation, and prescribing limits) that meets legal requirements and achieves a target budget impact of no more than $25 per student per year.",232,225,457,226,221,0.003556
2025-12-13T17:44:00,12,resp_003443a8aa32204800693d275028f4819883e40da835630994,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying an AI-driven mental-health screening program that uses short digital questionnaires and optional wearable sleep/activity data to flag students for counseling referrals, but it has recently faced a cluster of suicide attempts and is under pressure to act quickly. The superintendent needs an assessment that balances clinical validity and risk (false positives/negatives, triage capacity, and appropriate follow-up standards of care) with legal/regulatory constraints (FERPA for education records, HIPAA applicability for contracted providers, state minor-consent and mandatory-reporting laws, and requirements for parental notice/opt-out). Using the district’s projected student participation rate, the screening tool’s published sensitivity/specificity, counselor staffing levels, and expected referral-to-appointment timelines, quantify the expected number of flagged students per month, estimate downstream workload and wait times, and model the risk impact of delays on adverse outcomes using reasonable epidemiological assumptions. Based on that quantitative and legal-medical analysis, deliver a go/no-go recommendation and the minimum compliant policy package (consent language, data-retention and access controls, escalation protocols for imminent risk, and vendor contract requirements) the district must adopt before launch.",232,246,478,226,242,0.00385
2025-12-13T17:44:05,13,resp_0aa2b4600f560f2f00693d2755dcd48196816719aca6dc1a78,gpt-5.2,"[Origin Task]:
A mid-sized U.S. hospital system plans to launch an employer-sponsored “metabolic health” program for its 8,500 employees that includes GLP-1 medications, biometric screenings, and cash incentives for meeting weight-loss targets, and leadership needs to decide whether to roll it out in all states where it operates (including California and Texas). Using current clinical standards for GLP-1 prescribing and monitoring (contraindications, adverse event risks, follow-up cadence), applicable legal/regulatory constraints (ADA/GINA and EEOC wellness-program rules, HIPAA privacy and employer access limits, and state-specific rules affecting incentives and data handling), and a quantitative cost/benefit model (expected enrollment, medication + lab + clinician time costs, projected reductions in diabetes-related claims, absenteeism changes, and sensitivity analysis for adverse-event rates and discontinuation), evaluate whether the program can be designed to be both medically appropriate and legally compliant while meeting a target of at least 1.2:1 ROI within 24 months. Incorporate common-sense operational considerations such as supply shortages, staffing capacity, and employee trust/participation impacts if incentives feel coercive. Deliver a go/no-go recommendation and a proposed program design (incentive structure, eligibility criteria, privacy controls, and monitoring protocol) that minimizes legal risk and patient harm while achieving the ROI target.",232,281,513,226,277,0.00434
2025-12-13T17:44:12,14,resp_02b48a120f71d4f400693d275d175481909be8c16fec2de53d,gpt-5.2,"[Origin Task]:
A county public school district is considering deploying a new AI-powered “asthma safety” program that uses wearable pulse-oximeters and inhaler sensors for 1,200 students (ages 6–17) to detect respiratory distress and automatically notify the school nurse and parents, while also offering aggregated reports to the district and a research partner. The district must decide whether to proceed and, if so, what consent model, data-sharing terms, and clinical escalation protocol to adopt, ensuring compliance with FERPA and HIPAA boundaries, relevant state minor-consent and mandatory-reporting rules, and device/telehealth requirements while minimizing medical risk from false alarms or missed events. Using the vendor’s stated performance (sensitivity 92%, specificity 88%) and local prevalence estimates (8% of enrolled students have moderate-to-severe asthma; 0.6% weekly probability of an actionable event among those students), quantify expected weekly true/false alerts, nurse workload hours, and projected cost per averted emergency department visit under three policy options: opt-in parental consent, opt-out consent, and limiting alerts to nurse-only without parent notifications unless clinically confirmed. Deliver a recommendation on whether to launch, which policy option to choose, and the minimum legal/clinical safeguards and quantitative thresholds (e.g., alert confirmation rules) required before deployment.",232,274,506,226,270,0.004242
2025-12-13T17:44:21,15,resp_026bd8fb3690635700693d2765c0fc81948cbcaea08fd0dcd0,gpt-5.2,"[Origin Task]:
A US-based logistics company with 2,800 employees (40% in California, 60% in Texas) is considering rolling out an optional employer-sponsored program that provides continuous glucose monitors (CGMs) and telehealth coaching to reduce diabetes-related claims, but leadership is worried about HIPAA/ADA compliance, wellness-program incentive limits, and potential discrimination risks if participation is tied to premium discounts. Using the last 24 months of de-identified health plan data, the company estimates 310 employees have diagnosed type 2 diabetes, average annual diabetes-related paid claims are $9,400 per diagnosed employee, CGM + coaching would cost $1,800 per participant per year, and actuarial modeling suggests a 22% reduction in diabetes-related claims among participants with a 65% expected opt-in rate; however, the program may also increase short-term physician visits by an average of 0.4 visits per participant at $210 per visit. The CFO needs a quantified 3-year ROI range (best/base/worst case with reasonable assumptions), while the General Counsel needs a recommendation on a compliant program design (data handling, consent, reasonable alternative standards, and incentive structure) that minimizes legal exposure under HIPAA, the ADA, and relevant wellness-program rules for both California and Texas operations. Provide a single integrated recommendation on whether to launch the program next plan year and, if so, the specific incentive and privacy approach to adopt, grounded in the financial analysis and the regulatory/healthcare considerations.",232,308,540,226,304,0.004718
2025-12-13T17:44:29,16,resp_0f4cdf5cd2283e9700693d276d1fd88196893d706284e6b47a,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district plans to introduce an AI-assisted mental health screening program for students (ages 12–17) using a short questionnaire and optional telehealth follow-up, and needs to decide whether to run it as an “education record” program, a school health service, or through an external healthcare provider. Using the district’s projected participation rate (60% of 18,000 students), estimated false-positive/false-negative rates from published validation studies, and local clinician capacity (8 counselors + contracted telepsychiatry), quantify expected weekly referrals, urgent-risk escalations, and staffing needs, and estimate the annual cost under two vendor pricing models. At the same time, determine the compliance requirements and constraints under FERPA, HIPAA (if applicable), COPPA, and relevant state minor-consent and mandatory reporting laws, including what parental consent/opt-out language, data retention limits, and information-sharing boundaries are legally permissible. Finally, recommend which operational model the district should choose and provide a defensible rollout policy (consent workflow, triage protocol, and data governance) that minimizes clinical harm and legal exposure while meeting budget and capacity limits.",232,243,475,226,239,0.003808
2025-12-13T17:44:34,17,resp_0f9f33db4aa6f73900693d2772cf60819b8de75fe40d8d6ea1,gpt-5.2,"[Origin Task]:  
A mid-sized U.S. school district is considering implementing a pilot “test-to-stay” program to reduce COVID-19-related classroom disruptions: vaccinated and unvaccinated students exposed in class would remain in school if they are asymptomatic and receive daily rapid antigen tests for 7 school days, with positives isolated and offered confirmatory PCR through the district clinic. The district must ensure the program complies with applicable federal and state rules on student health records and consent (e.g., FERPA/HIPAA boundaries, parental consent requirements, mandatory disease reporting, and nondiscrimination obligations for students with disabilities), while also addressing clinical appropriateness (test performance characteristics, symptom screening, and medical referral thresholds). Using the provided inputs—2,400 students, average 18 close-contact exposures per school day districtwide, rapid antigen sensitivity 80% and specificity 99.5% in asymptomatic children, estimated asymptomatic infection prevalence among exposed students 6%, PCR cost $85, antigen cost $7, and an estimated $160 societal cost per missed student-day—quantitatively compare expected weekly costs and missed school-days under (A) 10-day home quarantine for all exposed students versus (B) test-to-stay with isolation only for positives (assume 5-day isolation and that each false positive causes the same isolation). Draft a decision memo recommending whether to launch the pilot and under what consent, privacy, and clinical safety safeguards, based on the combined legal compliance assessment, healthcare risk analysis, and the quantitative cost/benefit results.",232,318,550,226,314,0.004858
2025-12-13T17:44:42,18,resp_016d9acdcffe757b00693d277a4a4481968f0ab27f2a1a3e15,gpt-5.2,"[Origin Task]:
A mid-sized U.S. public school district is deciding whether to switch its cafeteria program to a “peanut-free campus” policy after several students with severe peanut allergy had emergency epinephrine use on school grounds this year, while also facing budget constraints and a proposed vendor contract change. Using current federal and state requirements for disability accommodations and student health records/privacy (e.g., Section 504/ADA, FERPA/HIPAA boundaries), clinical standards for anaphylaxis prevention and emergency response in schools, and quantitative analysis of incident rates and projected risk reduction, evaluate the legal and medical adequacy of three options: (1) maintain current allergen-aware practices, (2) implement peanut-free cafeterias only, or (3) implement a campus-wide peanut-free policy with enhanced staff training and stocking epinephrine. The district provides data on enrollment, documented allergy prevalence, past anaphylaxis incidents, response times, training costs, food procurement price changes, and expected compliance/enforcement costs; you must model the expected annual incidents avoided, expected cost per incident avoided, and potential liability exposure under each option. Account for practical considerations such as enforceability, equity impacts on student nutrition, and how accommodations would be documented and communicated without violating privacy rules. Deliver a recommendation for which policy to adopt for the next school year, including the defensible rationale balancing legal compliance, medical safety, and cost-effectiveness.",232,289,521,226,285,0.004452
2025-12-13T17:44:50,19,resp_026d77676dc2a92000693d278269a88199949f2d97225047b0,gpt-5.2,"[Origin Task]:
A regional hospital system that operates both an emergency department and an employer-sponsored health plan wants to launch an AI-assisted “rapid sepsis screening + telehealth follow-up” program for adults discharged from the ED, using EHR data and post-discharge wearable vitals to trigger nurse outreach within 6 hours. The board needs a decision memo that evaluates (1) clinical safety and medical appropriateness criteria for who can be enrolled or excluded (e.g., immunocompromised patients, pregnancy, recent surgery), (2) legal/regulatory compliance and liability exposure under HIPAA, state telemedicine consent rules, and FDA/FTC considerations for software that influences clinical decisions, and (3) a quantitative cost–benefit and risk analysis estimating expected changes in 30-day readmissions, sepsis-related mortality, staffing needs, and total program ROI under three uptake scenarios and two false-positive rates. Using the hospital’s last-year ED volume (120,000 visits), baseline 30-day sepsis readmission rate (2.1%), average cost per sepsis readmission ($38,500), proposed program costs ($2.4M fixed + $28 per enrolled patient + $95 per alerted patient), and an assumed relative readmission reduction range of 10–25% with uncertainty, determine whether the hospital should proceed, delay for a pilot, or abandon the program and specify the minimum performance thresholds (clinical and financial) required for go/no-go.",232,298,530,226,294,0.004578
2025-12-13T17:44:56,20,resp_0383d9f0bf340d9900693d278906848199b3ef89c57e903e08,gpt-5.2,"[Origin Task]:
A U.S.-based logistics company with 1,200 drivers is considering deploying an AI-enabled in-cab camera and wearable system to detect drowsiness and automatically trigger mandatory rest breaks, but the system would continuously collect biometric signals (heart rate variability) and short video clips that may capture medical symptoms. The company must decide whether to run the program nationwide or only in certain states, while complying with HIPAA boundaries (as an employer, not a healthcare provider), ADA restrictions on medical inquiries and fitness-for-duty actions, state biometric privacy laws (e.g., Illinois BIPA and similar statutes), and federal DOT hours-of-service rules, all while minimizing liability risk and preserving operational capacity. Using last year’s incident data (48 fatigue-related crashes; average crash cost $185,000; projected system cost $3.2M/year; expected crash reduction 25–40% with false-positive break triggers affecting 6% of driving hours), quantify the ROI range and operational impact, and determine the legally permissible data collection/retention and employee-notice/consent model. Provide a recommended go/no-go decision and a deployment policy that specifies which data are collected, how long they are retained, who can access them, and what employment actions (if any) are allowed when potential medical impairment is detected.",232,269,501,226,265,0.004172
2025-12-13T17:45:04,21,resp_0c2f211930ba4b2900693d2790647c8198a42f385b704599bb,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying an AI-assisted smartphone app that lets high-school athletes self-report concussion symptoms daily, triggers alerts to the school nurse and an affiliated sports-medicine clinic, and stores data in a vendor-managed cloud for 2 years. After a recent head-injury incident, the superintendent needs to decide whether to launch mid-season and, if so, what minimum consent, data-sharing, and clinical escalation rules must be in place to reduce medical risk while staying compliant with FERPA, HIPAA (for clinic interactions), state minor-consent/medical privacy requirements, and applicable breach-notification obligations. Using reasonable epidemiological assumptions for concussion incidence and false-negative/false-positive rates from the proposed screening questionnaire, estimate expected annual outcomes (missed concussions, unnecessary referrals, and downstream ED visits avoided) and compare them against projected costs (app licensing, nurse time, clinic follow-ups) to compute a cost per clinically significant concussion detected and a break-even point. Account for equity/common-sense operational constraints (students without smartphones, language access, coach override pressure) and quantify how alternative policy choices (opt-in vs opt-out, data retention length, notification thresholds) change both legal exposure and health outcomes. Provide a recommended go/no-go decision and the specific policy terms the district should adopt now (consent language elements, data access controls, retention/deletion schedule, and escalation criteria) based on your analysis.",232,295,527,226,291,0.004536
2025-12-13T17:45:10,22,resp_0acd3c51e101973500693d279681d8819aba20fc3cc209a2aa,gpt-5.2,"[Origin Task]:
A mid-sized U.S. hospital system is considering launching a pharmacist-led telehealth program to prescribe and mail nirmatrelvir/ritonavir (Paxlovid) to high-risk COVID-19 patients within 24 hours of a positive test, using a third-party courier and a centralized call center that would also handle medication reconciliation and follow-up adverse-event checks. The compliance team is concerned about federal and state requirements for pharmacist prescribing authority, telehealth rules, HIPAA/privacy (including texting results and sharing data with the courier), and whether the proposed workflow creates EMTALA risk when patients use the service instead of going to the ED. Clinicians want safeguards for renal/hepatic dosing, contraindicated drug–drug interactions, and documentation standards, while finance needs a quantitative estimate of cost-effectiveness and patient-safety impact using last winter’s data (test volume, hospitalization rate, average length of stay, program costs, and expected reduction in admissions if antivirals are started earlier). Using these constraints, determine whether the hospital should proceed and, if so, specify a compliant operational policy (eligibility criteria, consent/privacy approach, prescribing/dispensing model, and escalation thresholds) and a quantitative go/no-go decision supported by projected net savings and estimated clinical risk reduction for the next 6-month respiratory season.",232,271,503,226,267,0.0042
2025-12-13T17:45:16,23,resp_0ef3c32ea33858f200693d279c5ae88197bcb38c0fe71040c2,gpt-5.2,"[Origin Task]:
A mid-sized U.S. public school district is considering contracting with a telehealth vendor to provide after-hours pediatric urgent-care video visits for students (ages 6–17), including prescribing limited medications and sharing visit summaries with the school nurse and the district’s student information system. The district needs to decide whether and how the program can be launched while complying with HIPAA/FERPA boundaries, state minor-consent and telemedicine prescribing rules (including controlled-substance restrictions), mandated-reporting duties, and ADA/Section 504 accessibility requirements for students with disabilities and limited English proficiency. Using projected utilization (12,000 students; expected 8% annual visit rate; vendor fee $45 per visit plus $120,000 fixed annual platform cost) and the district’s current emergency transport costs (average $650 per ER transport; 35% of telehealth-eligible cases currently trigger transport), quantify the break-even point and estimate the annual net financial impact under best/base/worst-case clinical diversion assumptions, while also addressing clinical safety constraints (red-flag escalation protocols, continuity of care, and medication safety). Prepare a single board-ready recommendation on whether to proceed, and if so under what contract terms, consent workflow, data-sharing limitations, and clinical governance policies the district should require before launch.",232,266,498,226,262,0.00413
2025-12-13T17:45:23,24,resp_0a93aafd42227cc200693d27a321988190a36fb252a4c2c331,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system with 6,200 employees plans to launch an internal AI-driven “wellness analytics” program that ingests de-identified EHR data plus optional wearable glucose and heart-rate data to identify staff at elevated risk of diabetes and arrhythmia, then offers premium reductions and coaching; several unions allege it may violate HIPAA, the ADA/GINA, and state biometric privacy laws if participation is not truly voluntary or if incentives are coercive. The CFO needs a quantitative estimate of expected medical-claims savings versus program costs, including sensitivity to participation rates (30–70%), false-positive/false-negative screening performance, and the downstream clinical impacts (e.g., earlier diagnosis, medication adherence, and potential harms from unnecessary follow-ups). The compliance officer requires a determination of the minimum legal safeguards and notice/consent language needed to keep the program lawful (data minimization, separation from employment decisions, incentive caps, retention limits, breach response) and whether premium differentials could be construed as disability discrimination. Using reasonable assumptions and clearly stated calculations, provide a go/no-go recommendation with the smallest legally compliant incentive structure that still achieves a positive expected ROI within 24 months, and specify what medical oversight and referral pathways must be in place to meet standard-of-care and reduce liability.",232,271,503,226,267,0.0042
2025-12-13T17:45:31,25,resp_0f838894ae0740b100693d27abc09c819084902f52043bb204,gpt-5.2,"[Origin Task]:
A regional hospital system in the U.S. plans to deploy an AI-enabled “virtual nurse” app that collects patient-reported symptoms, medication adherence, and home vital signs (including optional pulse-ox readings) for post-discharge heart failure patients, and it wants to share weekly risk scores with its affiliated insurer to reduce readmissions. After a pilot, leadership must decide whether to (a) expand to all 8,000 eligible annual discharges, (b) limit enrollment to high-risk patients, or (c) stop the program, given concerns about HIPAA/privacy, state telehealth and nursing scope-of-practice rules, potential FDA “software as a medical device” implications, and clinical safety (e.g., false negatives delaying care). Using the pilot’s observed event rates and confusion-matrix metrics (provided in an internal memo), the cost of readmissions/ED visits, staffing costs for human escalation, and a proposed consent/data-sharing model, determine the legally compliant deployment option that maximizes expected net savings while meeting a specified patient-safety threshold (maximum allowable increase in adverse events), and draft the recommended policy decision with the quantitative justification and required compliance safeguards.",232,243,475,226,239,0.003808
2025-12-13T17:45:37,26,resp_0f78ae3966636b6d00693d27b1cdf88194a0ab5e98c29a12fb,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is considering launching an AI-driven remote patient monitoring program for 2,500 Medicare patients with congestive heart failure, where wearable devices transmit daily vitals to a vendor cloud and nurses intervene based on risk scores; leadership must decide whether to proceed and under what operational constraints. Using published CHF readmission rates and internal cost data, estimate the break-even point and expected annual net impact (including device costs, staffing, vendor fees, and avoided 30-day readmission penalties), and quantify how results change under best/worst-case adherence scenarios. At the same time, assess the program’s legal viability under HIPAA, the FTC Health Breach Notification Rule, Medicare RPM billing requirements, and state telehealth consent rules, including whether the vendor’s data use terms create unacceptable secondary-use or re-identification risks. Incorporate clinical safety considerations (e.g., false alarms, delayed escalation, equity impacts for patients with limited digital literacy) and propose a go/no-go recommendation with the minimum compliance, clinical governance, and monitoring metrics the hospital must adopt before contracting and enrolling patients.",232,228,460,226,224,0.003598
2025-12-13T17:45:43,27,resp_0956102ef1ae894800693d27b7a99481979bd2f84bb0403554,gpt-5.2,"[Origin Task]:
A mid-sized U.S. home-health company that serves Medicare beneficiaries wants to roll out an AI-driven remote patient monitoring program for congestive heart failure and diabetes patients using Bluetooth blood pressure cuffs, glucometers, and a symptom-checker app, and it must decide whether to launch in California and New York first. Using a proposed cohort of 1,200 patients, estimate the program’s expected annual impact on hospitalizations, net cost savings, and break-even monthly reimbursement by combining baseline admission rates, projected relative risk reductions from remote monitoring, device/app/support staffing costs, and an assumed distribution of adherence; then quantify how results change under best/base/worst scenarios. In parallel, determine the key legal/regulatory constraints (HIPAA and state privacy rules, FDA considerations for software as a medical device, Medicare billing rules for RPM/CCM, and clinician licensure/telehealth consent requirements) that could alter permissible data flows, staffing model, and reimbursement, and identify any “go/no-go” compliance blockers. Incorporate clinical safety considerations (triage thresholds, escalation pathways, and risks of false alerts or missed deterioration) to propose an operating policy that is medically defensible and reduces liability exposure. Based on your integrated quantitative, clinical, and legal analysis, recommend whether the company should launch in CA/NY now, delay for design changes, or pilot in a different state, and specify the minimum policy and contract terms required to proceed.",232,296,528,226,292,0.00455
2025-12-13T17:45:50,28,resp_0f7317908b1271d900693d27be26fc8194b618f797f1aa4d54,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying an AI-enabled smartphone app for high-school athletes that collects heart rate, sleep, and symptom surveys to flag possible concussion or heat illness and automatically notify the athletic trainer and a parent/guardian. The district must determine whether the data flows and vendor contract comply with HIPAA (where applicable), FERPA, and relevant state minor-consent and privacy rules, including what disclosures and opt-in/opt-out mechanisms are required for students aged 14–18. Using last season’s incident rates, test sensitivity/specificity assumptions from published sports-medicine studies, and a projected budget, quantify expected true/false alerts, staff workload hours, and cost per clinically meaningful event detected, and compare these to the medical risk of missed cases and the operational impact of unnecessary removals from play. Recommend whether to proceed, and if so, specify the minimum legally compliant consent language elements, data retention limits, and notification protocol the district should adopt under the proposed implementation.",232,208,440,226,204,0.003318
2025-12-13T17:45:56,29,resp_0a0f6eb5c6f4803a00693d27c45a7c819499e95af2163babb3,gpt-5.2,"[Origin Task]:  
A mid-sized U.S. public school district is considering deploying an AI-enabled camera and wearable sensor program to detect possible opioid overdoses and severe asthma attacks on campus, automatically alerting the nurse, 911, and designated staff while logging incidents for quality improvement. The district must decide whether and how to implement the program in compliance with FERPA, HIPAA boundaries for school health records, state minor-consent and mandatory reporting laws, and ADA accommodations—while ensuring clinical protocols (e.g., sensitivity/specificity tradeoffs, false-alarm risks, and escalation criteria) align with accepted medical practice and do not create foreseeable harm. Using the vendor’s validation data (e.g., sensitivity/specificity by condition), district incident rates, staffing constraints, and device/program costs, quantify expected true/false alerts, projected time-to-intervention changes, and cost-effectiveness (e.g., cost per serious adverse event averted) under at least two deployment options (all schools vs. high-risk schools only). Also assess liability exposure and required policy language for consent, data retention, access controls, and parental notification, including how to handle students who opt out or have 504/IEP plans requiring accommodations. Produce a recommendation on whether to proceed, which deployment option to choose, and the minimum legal/clinical safeguards and operating policies needed before launch.",232,278,510,226,274,0.004298
2025-12-13T17:46:02,30,resp_0da207cdc644f50a00693d27cab81481908efe6ec4326afd22,gpt-5.2,"[Origin Task]:
A U.S.-based school district is considering deploying an AI-supported “flu and strep triage” program in 12 middle schools, where a contracted nurse practitioner conducts telehealth visits, uses rapid tests on-site, and shares limited health data with the district to monitor outbreaks. District leadership needs to decide whether the program is legally permissible under HIPAA/FERPA and applicable state telehealth and minor-consent rules, and what minimum data elements and consent language are required to reduce liability while still enabling public-health reporting. Using last year’s absenteeism and nurse-office logs, estimate the expected reduction in missed school days and ER/urgent-care visits if test sensitivity/specificity and treatment adherence rates match published clinical ranges, and compute a cost-effectiveness comparison versus the current “send-home and recommend PCP” approach (include staffing, test kits, platform fees, and potential penalty exposure for noncompliance). Also assess medical safety considerations (false negatives, antibiotic stewardship, isolation guidance, and escalation criteria for red-flag symptoms) and how these affect the quantitative model and policy design. Deliver a go/no-go recommendation with a compliance-ready program design outline (data-sharing boundaries, consent workflow, reporting obligations, and safety protocols) supported by your calculations and legal/clinical rationale.",232,262,494,226,258,0.004074
2025-12-13T17:46:11,31,resp_00d174ea215e914300693d27d3caac819aaebc11e2d9f59d0a,gpt-5.2,"[Origin Task]:
A 450-employee manufacturing company in Illinois wants to roll out a voluntary “return-to-work health clearance” program after a spike in influenza and RSV cases, requiring employees to either provide a note from a clinician or complete a company-paid telehealth visit that may include a rapid test and a short symptom questionnaire. HR needs to know whether this program triggers obligations under ADA, HIPAA, OSHA recordkeeping, and Illinois privacy/biometric rules if the questionnaire is administered through a vendor app, and what limits apply to collecting, storing, and sharing results with supervisors. Finance also needs a quantitative recommendation comparing two options—(A) fully company-paid telehealth + testing for symptomatic employees vs. (B) a fixed stipend toward any outside clinician visit—by estimating expected annual cost, lost workdays avoided, and potential liability exposure using provided assumptions (employee count, baseline infection rate, test/visit costs, average hourly wage, average sick days, and probability-weighted legal/compliance penalties). As the consultant, deliver a single policy recommendation (choose A or B or a hybrid) with a legally compliant data-handling approach and the numeric justification for the chosen option, tailored to the company’s operational constraints and workforce mix.",232,252,484,226,248,0.003934
2025-12-13T17:46:17,32,resp_037bdb7c0e5419ba00693d27d94cc0819788679c822eb5b5f0,gpt-5.2,"[Origin Task]:
A mid-sized U.S. city’s public school district is considering launching a “test-to-stay” program for K–12 students during a respiratory virus surge, where symptomatic students are sent home, while close contacts of confirmed cases can remain in school if they test negative on rapid antigen tests for five consecutive school days and wear masks. The superintendent needs an analysis that integrates medical evidence on test sensitivity/specificity by day since exposure and the expected reduction in in-school transmission, compliance and staffing constraints, and applicable legal/regulatory requirements (e.g., state education rules, public health orders, HIPAA/FERPA privacy limits for reporting results, and disability/accommodation obligations under ADA/Section 504). Using district data (12,000 students, average 2.3 close contacts per case, current weekly incidence 1.2% with 15% week-over-week growth, test cost $6 each, nurse capacity 1,100 tests/day, and a goal of keeping weekly in-school secondary cases under 25), estimate whether the policy is feasible and cost-effective compared with a 5-day quarantine policy, including projected weekly secondary cases, testing volumes, and budget impact under best/base/worst compliance scenarios. Provide a recommendation on whether to adopt test-to-stay, what safeguards and consent/notification language are required to remain compliant, and the threshold metrics that should trigger tightening or suspending the program.",232,291,523,226,287,0.00448
2025-12-13T17:46:26,33,resp_00830c64f82ae02b00693d27e235c8819b9432599fe4b70e24,gpt-5.2,"[Origin Task]:
A U.S.-based public school district is considering installing UV-C air disinfection units and upgrading HVAC filtration to reduce respiratory infections, but must ensure compliance with OSHA indoor air guidance, EPA/FDA rules on UV-C devices and chemical disinfectants, and state public procurement and student privacy requirements when collecting health absenteeism data. The district has 42 schools with varying room volumes and ventilation rates, a fixed capital budget, and must estimate expected reductions in influenza/COVID transmission using published dose–response and air-change models while accounting for contraindications (e.g., asthma, photosensitivity risks, ozone generation limits) and maintenance/occupational exposure constraints. They also need a quantitative cost–benefit and risk analysis comparing UV-C vs. MERV-13/HEPA upgrades, including energy costs, device lifespan, projected avoided sick days, and uncertainty bounds, to justify a board vote and potential bond issuance. Provide a recommendation on whether to proceed, which technology mix to adopt, and what compliance controls and medical safety monitoring plan to implement before rollout.",232,217,449,226,213,0.003444
2025-12-13T17:46:31,34,resp_0425f3b2cff33ac500693d27e78b908197869b56c17b22b6f1,gpt-5.2,"[Origin Task]:
A mid-sized U.S. city’s public school district is considering launching a voluntary “test-to-stay” respiratory illness program in winter that would offer on-site rapid influenza/COVID testing and same-day telehealth evaluation for symptomatic students, while also collecting de-identified data to publish weekly outbreak metrics. District leadership needs to ensure the plan complies with federal/state requirements (e.g., student privacy rules, parental consent, public health reporting duties, telehealth and clinical testing regulations, and accommodations for students with disabilities), and that clinical workflows follow appropriate medical standards for triage, isolation recommendations, and referral for emergency care. They also must decide whether the program is cost-effective compared with closing classrooms, using quantitative modeling that estimates expected prevented absences and transmissions, staffing and test costs, false-positive/false-negative impacts, and the budget effect under different community prevalence scenarios. Draft a board-ready policy proposal that recommends whether to adopt the program, specifies the minimum legal/medical safeguards required to operate it, and includes a numerical cost–benefit comparison (with stated assumptions) against the district’s current “send home and quarantine” approach.",232,233,465,226,229,0.003668
2025-12-13T17:46:37,35,resp_095c80d87ce6818f00693d27edef788196aaa43f9a4f4d2c3e,gpt-5.2,"[Origin Task]:
A U.S.-based ride-share company is piloting an in-app feature that alerts drivers when a passenger may be experiencing an opioid overdose, using smartphone motion/audio patterns and an optional linkage to the passenger’s wearable heart-rate/SpO₂ data; the company wants to automatically notify 911 and share the rider’s real-time location and recent biometric indicators. Draft a go/no-go recommendation that evaluates compliance risks under HIPAA (including whether the company is a covered entity or business associate), applicable state privacy laws (e.g., California CPRA) and emergency-disclosure exceptions, plus potential liability exposure if the system fails to alert or alerts falsely. Using provided pilot data (base overdose prevalence 0.08% of rides; model sensitivity 92%, specificity 98.8%; 4 million rides/month), quantify expected true/false alerts per month, estimate EMS cost impact (assume $1,250 per dispatch) and expected health benefit using an assumed 7-minute earlier response improves survival by 12% among true overdoses, and compare outcomes under two threshold settings that change specificity to 99.6% but reduce sensitivity to 80%. Conclude with a concrete decision on whether to launch, delay, or limit the feature (e.g., opt-in only, geography-limited, human-in-the-loop), specifying the minimum policy language, consent flow, and clinical escalation protocol needed to be defensible.",232,292,524,226,288,0.004494
2025-12-13T17:46:44,36,resp_0a069181fd7acd3300693d27f48f60819a87cf3a59670f4723,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district plans to deploy an AI-driven camera system on school buses to detect possible asthma distress and opioid overdoses and automatically alert parents, EMS, and the district nurse, while also storing incident video and health notes in a cloud dashboard accessible to transportation staff. The superintendent needs to decide whether to launch a 6‑month pilot and, if so, what policy limits are required to comply with HIPAA/FERPA and relevant state privacy/biometric laws, including consent, data retention, access controls, and permissible disclosures during emergencies. Using last year’s bus incident logs (220,000 student-rides/week; 34 respiratory emergencies; 6 suspected overdoses; average EMS response 11 minutes) and vendor claims that alerts reduce time-to-intervention by 3.5 minutes and cut hospitalization probability by 18% in true-positive cases but produce a 0.12% false-alarm rate per ride, estimate expected changes in EMS calls, hospitalizations avoided, and annual cost impact given $900 per EMS dispatch, $7,500 per hospitalization, $420,000 pilot cost, and an assumed statistical value of life-year framework provided by the district’s insurer. Based on these quantitative results and medical appropriateness (e.g., triage safety of false alarms) alongside legal compliance constraints and operational common-sense considerations (staff workload, parent trust, equity), draft a recommendation on whether to proceed and specify the minimum policy and contractual requirements the district must impose on the vendor and staff before deployment.",232,316,548,226,312,0.00483
2025-12-13T17:46:51,37,resp_063ede1a3e16b4ae00693d27fb7cac8198bec523876b735e40,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is planning to deploy a generative-AI chatbot on its patient portal to answer post-discharge questions for cardiac patients (medication dosing reminders, symptom triage, and scheduling), and to automatically summarize chat transcripts into the electronic health record; leadership must decide whether to launch systemwide next quarter or limit to a pilot. Using HIPAA and applicable state privacy/consent rules, FDA guidance on clinical decision support software, and standard-of-care considerations for cardiac symptom triage, determine what legal/clinical safeguards are required (e.g., human review thresholds, emergency escalation language, data retention, and patient consent). Quantitatively estimate the expected annual impact on adverse events and costs by modeling call-center deflection, probability of delayed care from incorrect advice, and downstream utilization (ED visits/readmissions), including sensitivity analysis under different error rates and patient adoption levels. Incorporate practical constraints such as staffing limits, multilingual access, and equity impacts on older adults and low-health-literacy patients to assess feasibility and risk. Based on this integrated analysis, produce a go/no-go recommendation and specify the exact deployment scope and policy conditions the hospital should adopt.",232,243,475,226,239,0.003808
2025-12-13T17:46:56,38,resp_0d7149681a215f5c00693d2800d7ec8197bb3b95a1f4ce1198,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering launching an after-hours telehealth program to provide same-day evaluation and treatment for students with asthma exacerbations and suspected influenza/COVID, staffed by a contracted pediatric group and supported by a mobile clinic that can administer nebulized albuterol and rapid tests on campus. The district must determine whether the program can legally operate under federal and state rules (e.g., HIPAA/FERPA coordination, minor consent, standing orders/prescribing, and emergency medication administration on school property) and what clinical protocols are required to keep care within standard-of-care while minimizing avoidable ER transfers. Using last year’s attendance, nurse office visit logs, and local hospitalization rates, estimate expected utilization, per-encounter costs, and projected reductions in ER visits/ambulance calls, then perform a break-even and sensitivity analysis under different staffing and equipment assumptions. Based on those legal constraints, clinical safety requirements, and quantitative results, recommend whether to proceed, what operating model to adopt (district-run vs. vendor-run), and the minimum documentation/consent workflow needed before the pilot can start next semester.",232,233,465,226,229,0.003668
2025-12-13T17:47:04,39,resp_0c605a35c875db5700693d280832988198863f5d7c73d415c0,gpt-5.2,"[Origin Task]:
A U.S.-based hospital system with clinics in California and New York plans to deploy an AI-driven remote patient monitoring program for 2,500 Medicare patients with heart failure using Bluetooth scales and blood-pressure cuffs, with alerts routed to a 24/7 nurse triage vendor, and leadership must decide whether to launch in both states next quarter. Using projected hospitalization reduction rates from a pilot (absolute reduction 3.2% over 6 months), expected device adherence (72%), baseline 6‑month readmission rate (18%), and per-readmission cost ($14,800), quantify the program’s net financial impact under three adoption scenarios (50%, 75%, 90%) after accounting for device, staffing, and vendor costs, and include sensitivity to false-positive alert rates (5–20%) that drive additional nurse time. In the same memo, assess the key regulatory and legal constraints that could block or materially change the rollout—HIPAA/privacy and security obligations for the vendor relationship, state-specific telehealth and scope-of-practice rules for nursing triage, informed consent and data-sharing requirements, and any Medicare RPM billing or documentation constraints that affect reimbursement assumptions. Finally, recommend whether to launch in both states, one state, or delay, and specify the minimum compliance and clinical safety controls (e.g., escalation protocols for hypertensive crisis, device failure handling, and patient exclusion criteria) required to reduce medical risk while keeping the business case viable.",232,299,531,226,295,0.004592
2025-12-13T17:47:09,40,resp_0c69c19a1929bd5e00693d280e142481999c912bc0208e3057,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering adopting an AI-assisted asthma screening and medication adherence program for students, using inhaler sensor data and nurse-entered symptom logs to trigger automated parent notifications and referrals to a telehealth partner. The district needs to determine whether the data flows and consent model comply with applicable privacy and health regulations (e.g., FERPA, HIPAA considerations for the telehealth vendor, and state minor-consent and data-retention rules), and whether the clinical protocol meets standard-of-care expectations for pediatric asthma triage and emergency escalation. Using last year’s attendance records, nurse visit logs, and local hospitalization rates, estimate the program’s expected impact on missed school days and ER visits and perform a cost–benefit analysis under three adoption/engagement scenarios, including sensitivity to false-positive/false-negative screening rates and vendor subscription pricing. The district must also assess equity implications (e.g., differential access to smartphones for sensor syncing) and quantify how mitigation options (loaner devices, offline syncing) change both compliance risk and program ROI. Prepare a recommendation memo to the school board on whether to proceed, modify, or reject the program, specifying the minimum legal/clinical safeguards and the financial threshold at which the program becomes justified.",232,258,490,226,254,0.004018
2025-12-13T17:47:16,41,resp_0ae21f18fb9e2c6100693d281488a081908092ceb7393bc89d,gpt-5.2,"[Origin Task]:
A mid-sized U.S. public school district is considering implementing an AI-assisted medication-administration and symptom-triage program run by school nurses for students with asthma, ADHD, and severe allergies, where parents can opt in to a mobile app that shares limited health data with a contracted telehealth provider. The district must determine whether the proposed workflows and data-sharing (including parental consent handling, emergency exceptions, record retention, and vendor access) comply with applicable federal/state requirements such as FERPA, HIPAA (if triggered by the telehealth relationship), and state nurse practice/standing-order rules, while also ensuring clinically safe triage thresholds for when to call 911 or require in-person evaluation. Using last year’s nurse office-visit logs, medication error reports, and local EMS response-time statistics, estimate the expected change in adverse events and costs under the program (including staffing time, vendor fees, and liability exposure) and assess whether the reduction in risk is statistically and financially meaningful. Based on these legal, clinical, and quantitative findings, deliver a go/no-go recommendation and specify the minimum policy safeguards and operational constraints required before launch.",232,234,466,226,230,0.003682
2025-12-13T17:47:23,42,resp_03b314ed9e226dcf00693d281b56f8819b8e7965a96239a8bb,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying an AI-supported telehealth kiosk program in 12 high schools to screen and manage student asthma and anxiety, staffed remotely by nurse practitioners and integrated with the district’s electronic student health records. The superintendent needs a decision memo that evaluates (1) medical safety and standard-of-care considerations for triage, medication refills, and emergency escalation; (2) legal/regulatory compliance with HIPAA vs. FERPA, state minor-consent and parental notification rules, telemedicine licensing across state lines for contracted clinicians, and data retention/audit requirements; and (3) a quantitative cost–benefit and risk analysis projecting changes in ER visits, missed school days, clinician workload, and liability exposure under three utilization scenarios using the district’s last 3 years of asthma incidents and attendance data. The district also wants to know whether offering the service to uninsured students could create anti-kickback, Medicaid billing, or inducement issues, and how to structure vendor contracts and consent forms to mitigate them. Prepare a recommendation on whether to proceed, and if so, specify the compliance constraints, clinical scope limits, and financial thresholds that must be met before launch.",232,247,479,226,243,0.003864
2025-12-13T17:47:28,43,resp_083405147e8f0f9000693d282104fc819a87be8cbd0c98e271,gpt-5.2,"[Origin Task]:
A mid-sized U.S. city’s public school district is considering launching a pilot program to administer a long-acting injectable medication for students with severe asthma at school (with parent/guardian consent) to reduce ER visits and missed class time, but the teachers’ union and school nurses raise concerns about scope-of-practice, medication storage/handling, and liability if an adverse reaction occurs. The superintendent asks you to evaluate whether the program can be designed to comply with applicable federal and state requirements (e.g., student privacy, informed consent, and administration of prescription drugs in schools), while aligning with clinical best practices for asthma management and emergency response. You must also quantify the expected impact and cost-effectiveness using district data (e.g., asthma prevalence, historical absenteeism, ER transport rates, medication and staffing costs), including scenario analysis for different consent uptake rates and adverse-event probabilities. Considering operational constraints (nurse staffing, training time, refrigeration/security, and emergency protocols), produce a recommendation on whether to proceed with the pilot, and if so, define the compliant program parameters and the go/no-go decision thresholds the district should adopt.",232,233,465,226,229,0.003668
2025-12-13T17:47:34,44,resp_0f5df84ccfcb1fa700693d2826c2908197901e5c2ce47c38f4,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering launching an optional “flu + COVID-19 booster” vaccination clinic for staff and students (ages 12–17) during school hours, using a contracted pharmacy and storing limited doses on-site for two days at a time. The district’s board needs a decision memo that determines whether and how the program can legally operate (including parental consent rules for minors, HIPAA vs. FERPA data handling, ADA accommodations for medically contraindicated individuals, and state immunization/medical privacy requirements), while also assessing medical safety protocols (screening for contraindications, anaphylaxis response readiness, and infection-control measures). Using district-specific numbers (enrollment, staff headcount, historical absenteeism, vaccine uptake estimates, adverse event rates, and per-dose + staffing costs), quantify expected benefits and risks in a cost–benefit and risk analysis (e.g., projected reduction in sick days, avoided substitute-teacher costs, clinic throughput constraints, and expected adverse-event incidence with confidence bounds), and compare at least two operational models (in-school clinic vs. off-site vouchers). Deliver a final recommendation on whether to proceed and, if so, the minimum compliant policy set and operational parameters (who is eligible, consent and documentation workflow, data retention/sharing rules, staffing and emergency equipment, and a budget cap) that the board should adopt this month.",232,285,517,226,281,0.004396
2025-12-13T17:47:41,45,resp_066daf9f71cb2f1200693d282e0388819887853082f46a58fd,gpt-5.2,"[Origin Task]:  
A U.S. public school district is considering installing UV-C air-disinfection units and upgrading HVAC filtration across 12 schools to reduce seasonal influenza and COVID-19 transmission, using nurses’ visit logs and absenteeism data from the last two years. The district must ensure the plan complies with OSHA workplace safety rules for staff, EPA/FDA device claims restrictions, and student privacy requirements under FERPA/HIPAA-adjacent practices when using health data for evaluation and reporting. The superintendent needs a quantitative cost–benefit and risk analysis estimating infections averted, expected reduction in nurse visits/absences, and budget impact under different uptake and efficacy assumptions, while also accounting for medical contraindications (e.g., asthma triggers, UV exposure risks) and operational constraints (maintenance, room occupancy, ventilation rates). Produce a decision memo recommending whether to proceed, which schools to prioritize, what safeguards and consent/notice language are required, and how to structure a compliant pilot study with measurable outcomes and a go/no-go threshold.",232,211,443,226,207,0.00336
2025-12-13T17:47:47,46,resp_02260b2e51830e7700693d283368488198b3a1639b3e1bd911,gpt-5.2,"[Origin Task]:  
A U.S.-based retail company with 1,200 employees (40% in California, 60% in Texas) wants to launch an employer-sponsored weight-management benefit that includes GLP‑1 medications, telehealth prescribing, and an on-site nurse program, while also offering a $45/month premium discount to participants who meet quarterly biometric targets. After a recent internal audit found higher-than-expected adverse events (including pancreatitis flags) and a 28% year-over-year rise in pharmacy spend, leadership needs to decide whether to continue, modify, or pause the program for the next plan year. Evaluate the program’s medical safety and clinical appropriateness criteria (including monitoring protocols and contraindication handling), quantify the expected 12‑month net financial impact under three policy options (status quo, tighter eligibility/step therapy, or discontinuation) using provided enrollment projections and adverse-event rates, and assess the legal/regulatory risks of the incentive design and health data flows (HIPAA/ERISA/ACA wellness program rules, ADA/GINA considerations, California privacy requirements, and telehealth prescribing constraints). Based on that combined analysis, produce a board-ready recommendation on which option to adopt and the minimum compliance and clinical safeguards required before renewal.",232,257,489,226,253,0.004004
2025-12-13T17:47:55,47,resp_0f474d5a006ec92400693d283b7d54819ba53dc98c1db35c9b,gpt-5.2,"[Origin Task]:
A U.S. public school district is considering launching an opt‑out, in‑school asthma screening program for 2,500 students using handheld spirometry and a brief symptom questionnaire administered by contracted nurses, with results shared with parents and the district’s student health office to coordinate follow‑up care. The district must decide whether the planned data handling (collection on tablets, storage in a cloud vendor, and limited sharing with teachers for accommodations) triggers HIPAA, FERPA, and any state minor‑consent/privacy requirements, and what consent/notice language and access controls are legally necessary. Clinically, the district needs to set a screening threshold and referral protocol that balances false positives/negatives and accounts for medication access and emergency response policies. Financially, the superintendent needs a quantitative cost‑benefit estimate comparing program costs ($38 per student screened plus $140 per referral visit on average) to expected reductions in ER visits and absenteeism, given baseline asthma prevalence (12%), current annual ER visit rate among asthmatic students (0.18 per student), an estimated 30% ER reduction if uncontrolled asthma is identified and treated, and an average $1,200 cost per ER visit plus $65 per absent day in state attendance funding. Provide a recommendation on whether to proceed and, if so, specify the legally compliant operating model and the screening/referral thresholds that maximize net benefit while minimizing medical and privacy risks.",232,293,525,226,289,0.004508
2025-12-13T17:48:02,48,resp_0f87296b271ab91400693d284229448197a9a9406828fcac0c,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is planning to launch an AI-assisted medication reconciliation program across its emergency departments to reduce adverse drug events, using a vendor model that ingests EHR data and patient-reported supplements and then suggests dose adjustments for high-risk drugs (e.g., warfarin, insulin, opioids). The board needs a decision memo that evaluates (1) clinical safety and standard-of-care implications for implementing AI recommendations in acute care, (2) regulatory and legal compliance duties under HIPAA, state privacy laws, FDA/FTC oversight of clinical decision support, and malpractice/liability exposure if clinicians override or follow AI output, and (3) a quantitative cost–benefit and risk analysis estimating expected annual prevented adverse events, net savings, staffing impacts, and potential litigation/penalty costs under different adoption and error-rate scenarios using provided baseline event rates and volume assumptions. The program would also include an opt-out consent workflow and a plan to share de-identified data back to the vendor for model improvement, raising questions about permissible data use and patient rights. Prepare a recommendation to approve, modify, or reject the rollout and specify the minimum governance controls (clinical protocols, auditing, consent language, and vendor contract terms) required before go-live.",232,260,492,226,256,0.004046
2025-12-13T17:48:08,49,resp_0f9fb4ffdc88f05c00693d2848c9b881909f1543b7d949550c,gpt-5.2,"[Origin Task]:
A U.S.-based home health agency operating in California and Texas plans to deploy an AI-supported remote patient monitoring program for 1,200 Medicare patients with heart failure and diabetes, using Bluetooth blood-pressure cuffs and glucometers that transmit data to a cloud vendor and trigger nurse outreach plus medication adjustments under physician standing orders. The agency must decide whether to launch in Q2, given HIPAA/HITECH and state privacy requirements (including business associate agreements, minimum necessary access, breach-notification exposure, and constraints on cross-state telehealth practice and e-prescribing), and clinical safety obligations to avoid delayed escalation for abnormal readings. Using the vendor’s quoted pricing ($18 per patient-month device rental, $6 per patient-month data platform, and $95 per nurse call episode) and internal projections (average 0.35 nurse calls per patient-month; expected 14% reduction in 30-day readmissions from a baseline 18% readmission rate; average readmission cost to the agency under value-based contracts $9,800; and an estimated annual 2.2% probability of a reportable data breach with an expected all-in cost of $420,000 per breach), determine the expected net annual financial impact and whether the program should be launched as-is, delayed pending legal/clinical controls, or redesigned. Provide a go/no-go recommendation that explicitly integrates regulatory compliance feasibility, patient-safety risk management, and the quantitative cost–benefit results, and specify what decision the executive team should take this quarter.",232,312,544,226,308,0.004774
2025-12-13T17:48:17,50,resp_066d0136b22b8d9200693d2851ab40819887d731ff3c878379,gpt-5.2,"[Origin Task]:
A 600-employee manufacturing company in Illinois plans to add an on-site health clinic that offers flu/COVID vaccination, basic urgent care, and optional biometric screenings, and it wants to incentivize participation by reducing monthly health-insurance premiums for employees who complete the screening and follow-up coaching. After a recent incident where an employee fainted during a blood draw and later alleged improper medical supervision and privacy violations, the company must redesign the clinic workflow, consent forms, staffing model (RN vs NP/PA vs physician oversight), and data-sharing boundaries between the clinic vendor and HR/benefits. Using applicable U.S. legal/regulatory requirements (e.g., HIPAA, ADA, GINA, OSHA/recordkeeping, and wellness program rules), medical standards of care and contraindications for vaccinations/blood draws, and quantitative analysis of expected adverse-event rates, staffing coverage needs, and projected cost savings vs liability exposure, determine whether the incentive program and clinic services can be implemented as planned or must be modified. Provide a final recommendation on the compliant clinic operating model and incentive structure, including numerical thresholds (e.g., staffing ratios, emergency equipment/training requirements, and maximum premium differential) that keep medical risk and legal risk within acceptable limits while meeting the company’s cost target.",232,262,494,226,258,0.004074
2025-12-13T17:48:23,51,resp_0097da462be5676400693d2857f28c819a961c7b4f4a70807e,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering launching an opt-in program to provide a new long-acting asthma medication (administered monthly) to eligible students through school nurses, funded by a state grant and partially billed to families’ insurance. District leadership needs to decide whether the program is legally compliant and financially viable while minimizing health risks: they must account for parental consent requirements, HIPAA/FERPA data-sharing constraints between the district and a contracted pediatric clinic, state nurse scope-of-practice rules for medication administration, and potential liability exposure if adverse reactions occur on campus. Using the district’s last two years of asthma-related nurse visits and 911 calls, medication efficacy and adverse-event rates from published clinical data, and the grant/insurance reimbursement terms (including expected denial rates and copays), estimate the program’s expected annual impact on emergency transports, total net cost (or savings), and the probability of at least one severe adverse event occurring during the school year. Based on those quantitative results and the regulatory constraints, produce a recommendation on whether to proceed, what eligibility/consent and data-handling policy to adopt, and what minimum staffing/training and emergency-response protocol changes are required before rollout.",232,249,481,226,245,0.003892
2025-12-13T17:48:29,52,resp_0938e50a03498e1f00693d285d94388198843690e59e540e66,gpt-5.2,"[Origin Task]:
A U.S.-based county public health department plans to deploy an AI-assisted telehealth program for hypertension management that ships Bluetooth blood-pressure cuffs to 8,000 Medicaid patients, escalates readings to nurses, and automatically triggers same-day urgent-care referrals above configurable thresholds. The department must decide whether to run the program in-house or contract a vendor, while ensuring compliance with HIPAA (including BAAs and minimum necessary), state telemedicine prescribing/referral rules, and FDA considerations for software as a medical device, and it must also address clinical safety concerns such as false positives/negatives, appropriate escalation protocols, and patient harm mitigation. Using the provided pilot data (sensitivity 0.88, specificity 0.93 for detecting “dangerously high BP” episodes; estimated prevalence 6% per month; average cost per nurse escalation $18; urgent-care referral cost $240; expected cost of an untreated true dangerous episode $4,500; vendor fee $22 per patient-month; in-house fixed cost $420,000/year plus $6 per patient-month), quantify expected monthly total cost and expected avoided harm under three candidate alert thresholds (given as three sets of sensitivity/specificity), and recommend a threshold and operating model that is legally compliant, clinically defensible, and cost-effective. Deliver a brief decision memo with the chosen model, threshold rationale, key compliance actions (contracts, notices/consents, documentation), and quantitative results.",232,297,529,226,293,0.004564
2025-12-13T17:48:35,53,resp_0079a76b626a448e00693d2863d87c819a8194a5d6fed5d519,gpt-5.2,"[Origin Task]:
A regional hospital system is considering launching an AI-assisted telehealth program to prescribe Paxlovid for high-risk COVID-19 patients within five days of symptom onset, using a third-party vendor to collect patient data and run medication-interaction checks. Hospital leadership needs to decide whether the program is legally and clinically safe across two states with different telemedicine and e-prescribing rules, while ensuring HIPAA compliance and appropriate informed-consent language for patients who may have chronic kidney disease or are taking contraindicated medications. Using last winter’s patient volume, expected positivity rates, estimated eligibility percentages, adverse-event probabilities, and vendor fees, quantify the program’s projected net clinical benefit (e.g., hospitalizations avoided) and financial impact (costs, reimbursements, and liability exposure), and compare it to a “standard care” baseline. Based on this analysis, recommend whether to launch, modify, or defer the program, and specify the minimum compliance/clinical guardrails that must be in place at go-live.",232,207,439,226,203,0.003304
2025-12-13T17:48:40,54,resp_01524c7192e5420100693d2868d888819aad5314820671f322,gpt-5.2,"[Origin Task]:  
A mid-sized U.S. school district is deciding whether to install UVC air-disinfection units and upgrade HVAC filtration across 40 schools to reduce respiratory virus spread, but must ensure compliance with OSHA workplace safety rules, EPA pesticide/device regulations, and applicable state indoor air quality and procurement requirements. The district’s medical advisory board wants the plan to reflect current clinical evidence on UVC exposure risks (skin/eye injury), asthma/COPD considerations, and expected reductions in influenza/COVID absenteeism, while the finance office needs a quantitative cost–benefit analysis that includes capital costs, maintenance, energy use, device lifetime, and uncertainty ranges. The district also needs a legally sound consent/notification approach for staff, students, and visitors, including accommodation policies for medically vulnerable individuals and a process for incident reporting and liability risk management. Using these constraints, produce a recommended go/no-go decision and a policy-ready implementation proposal (including budget envelope, deployment prioritization, and compliance documentation) that the superintendent can submit to the school board next month.",232,216,448,226,212,0.00343
2025-12-13T17:48:45,55,resp_0408bd698426ea5600693d286e1adc81969f22788722f09bdc,gpt-5.2,"[Origin Task]:  
A U.S.-based public school district is considering launching a volunteer, opt-in program to provide rapid strep testing and same-day first-dose antibiotic dispensing to students in school health offices to reduce absences and community spread. District leaders need to determine whether the program can be structured to comply with applicable legal requirements (e.g., CLIA-waived testing rules, state scope-of-practice limits for school nurses, parental consent, HIPAA/FERPA data handling, and any mandatory reporting obligations) while meeting clinical standards of care (when to test/treat, contraindications, allergy screening, and referral thresholds). Using last year’s attendance and nurse-visit data (given: 18,000 students; 2,400 sore-throat visits; 28% historically strep-positive when tested; average 1.8 school days missed per confirmed case; proposed test cost $7 each; antibiotic course cost $5; staff time 12 minutes per test at $36/hour fully loaded; anticipated participation 60%; expected false-negative rate 8% and false-positive rate 3%), estimate the program’s annual net budget impact and projected reduction in missed school days under realistic assumptions. Based on the combined legal feasibility, clinical risk profile, and quantitative cost/benefit results, write a recommendation to the school board on whether to proceed and, if so, what minimum policy constraints (consent language, data retention/access, staffing model, and clinical protocols) must be adopted before implementation.",232,307,539,226,303,0.004704
2025-12-13T17:48:53,56,resp_09babb7a553dc30a00693d2875556c819a8b19fb8c4cf469e9,gpt-5.2,"[Origin Task]:  
A U.S.-based public school district is considering installing ionizing air purification units in 40 classrooms to reduce respiratory illness, but several teachers are pregnant and the district nurse reports a cluster of asthma exacerbations and one immunocompromised student per grade. The superintendent needs an assessment that combines clinical risk (expected changes in asthma attacks and infection-related absences), regulatory compliance (OSHA indoor air quality duties, state public-school health regulations, and any FDA/FTC constraints on health efficacy claims in procurement and parent communications), and a quantitative cost–benefit model using the vendor’s stated ozone byproduct rate, classroom ventilation rates, and historic absenteeism/health-office visit data. The school board also requires an equity impact analysis to ensure the rollout does not disproportionately affect students with disabilities under ADA/Section 504 and that accommodations are feasible without stigmatizing individual students. Prepare a decision memo recommending whether to purchase, reject, or pilot the units, specifying the legally compliant communication language and the minimum monitoring plan and thresholds that would trigger removal or expansion.",232,219,451,226,215,0.003472
2025-12-13T17:48:58,57,resp_0d10a4ba8634df2d00693d287a4f048193886f778ec948088d,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering contracting with a telehealth vendor to offer ADHD and anxiety evaluations for students (ages 12–18) after a rise in behavioral incidents, with optional prescription management and data sharing to school counselors for “academic support.” The superintendent needs a recommendation that balances clinical appropriateness (screening criteria, contraindications, and referral triggers), legal compliance (FERPA vs. HIPAA applicability, state minor-consent rules for mental health services, mandated reporting duties, and limits on sharing diagnostic/medication details with educators), and quantitative impact (projecting annual program cost, expected utilization, sensitivity analysis on false-positive rates, and estimating the effect on disciplinary actions and attendance using last year’s incident data). A parent coalition is threatening legal action if the program results in stigma or improper disclosure, while the vendor claims it can reduce suspensions by 15% and will store data in the cloud outside the state. Draft a decision memo to the school board that recommends whether to proceed, under what contract terms and clinical safeguards, and includes a quantified cost–benefit and risk analysis sufficient for a board vote next month.",232,238,470,226,234,0.003738
2025-12-13T17:49:05,58,resp_0acc62e5a0c707ed00693d288165c08195b59392f4dcbeac5e,gpt-5.2,"[Origin Task]:
A U.S. public school district is considering launching a voluntary after‑school “Healthy Sleep & Stress” program that includes collecting students’ wearable sleep/heart‑rate data, brief mental‑health screenings by a contracted telehealth clinic, and optional referral to a local pediatric practice, with parents able to opt in via an online portal. The district needs to determine what consents and privacy safeguards are legally required (e.g., FERPA, HIPAA, state minor‑consent and telehealth rules, and data‑sharing contracts), what clinical protocols are medically appropriate for screening and referral (including handling of self‑harm risk and mandatory reporting), and whether the program is financially viable given a $250,000 annual budget. Using the district’s projected participation rate (35% of 4,000 middle‑school students), expected false‑positive rates of the screening tool (8%), average telehealth visit cost ($65), and expected downstream referral rate among positives (40%) with average in‑person visit cost ($180), the district wants a quantitative estimate of annual program costs and the maximum wearable vendor price per student per year it can afford while maintaining a 10% contingency reserve. Draft a decision memo recommending whether to proceed, specifying the required legal compliance plan, the medical workflow and risk‑management policy, and the pricing ceiling the district should negotiate with the wearable vendor.",232,283,515,226,279,0.004368
2025-12-13T17:49:13,59,resp_0af311e46fe354cb00693d28894208819a854dd9d06b1ba748,gpt-5.2,"[Origin Task]:
A U.S.-based school district is considering deploying an AI-assisted mental-health screening program for students ages 12–18 that uses a short in-app questionnaire plus optional wearable heart-rate variability data to flag elevated depression/suicide-risk and automatically schedule telehealth follow-ups through a contracted clinic. The district’s general counsel is worried about compliance with FERPA and HIPAA, state minor-consent and mandatory reporting laws, and whether parents must opt-in or can be offered an opt-out—especially when the tool may generate false positives that trigger interventions. The health services director also needs to estimate clinical capacity and safety impact by modeling expected flagged cases, sensitivity/specificity tradeoffs, staff time per follow-up, and projected reduction in crisis incidents using last year’s incidence rates and a proposed screening cadence, while accounting for disparities and accommodations for students with disabilities. The superintendent wants a recommendation on whether to proceed, under what consent/data-governance and clinical escalation policy, and what staffing/budget is required to meet legal obligations and acceptable risk thresholds for harm from missed cases versus unnecessary interventions.",232,224,456,226,220,0.003542
2025-12-13T17:49:18,60,resp_0fa1555c8be7e4d600693d288ef68c8190be245de479cf0a4e,gpt-5.2,"[Origin Task]:  
A U.S.-based home health company operating in California and Texas is considering deploying a smartphone app that uses an on-device machine-learning model to flag early signs of sepsis in recently discharged patients, automatically notifying a 24/7 nurse triage line and (when configured) the patient’s designated family caregiver. Before launch, the company needs to determine whether the app’s messaging and workflows would be regulated as a medical device and what privacy/consent obligations apply under HIPAA, state privacy laws, and telehealth/clinical decision support rules, including how to handle minors and incapacitated adults. Using the company’s pilot data (10,000 patients; sepsis prevalence 1.2%; model sensitivity 84% and specificity 92%; nurse call costs $18 per outreach; average ED visit cost $1,900; estimated 22% ED-visit reduction among true positives who receive an outreach within 2 hours; estimated harm cost of $6,000 per false negative due to delayed care), quantify expected monthly net cost/savings and patient-safety impact under two alert thresholds (current metrics vs. a more conservative threshold with sensitivity 75% and specificity 96%). Incorporate practical clinical considerations (triage capacity limits of 1,200 outreaches/month, acceptable false-alarm burden, escalation criteria) and legal risk exposure (documentation, liability, required disclaimers, data retention, and breach notification) into a recommendation. Provide a go/no-go decision and a proposed compliant operating policy (who is contacted, when, what is documented, and how consent and opt-out are managed) that fits both states’ requirements.",232,337,569,226,333,0.005124
2025-12-13T17:49:26,61,resp_02d1950817efd26d00693d289696d08190a1f85117a6e7e5c9,gpt-5.2,"[Origin Task]:  
A U.S. public school district is considering deploying an AI-enabled fever-and-symptom screening kiosk at middle schools to reduce influenza/COVID-19 outbreaks, but it would collect temperature readings, reported symptoms, and student identifiers and automatically notify parents and the school nurse. Using applicable federal and state requirements (including FERPA, HIPAA boundaries for school health services, and state biometric/health data privacy rules), determine whether the district can lawfully collect, store, and share these data with its contracted kiosk vendor and local public health department, and specify the minimum consent, notice, retention, and security controls needed. Then, using last year’s attendance and clinic-visit records, estimate the expected reduction in transmission-related absences and the program’s cost-effectiveness by calculating expected cases averted, staff time saved, and the break-even per-student annual cost under at least two sensitivity scenarios (e.g., different false-positive/false-negative rates and community prevalence). Finally, provide a recommendation on whether to proceed this semester, including a go/no-go decision threshold and the conditions under which the district should pause or terminate the program.",232,235,467,226,231,0.003696
2025-12-13T17:49:33,62,resp_0b2188ca24a51b7000693d289d4c488199870f7c19f3f67666,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is deciding whether to implement a new policy allowing trained staff to administer intranasal naloxone and stock epinephrine auto-injectors on all campuses after several student overdoses and severe allergy incidents, and it must ensure compliance with state “stock medication” statutes, parental consent rules, Good Samaritan/immunity provisions, HIPAA/FERPA privacy requirements, and OSHA workplace training obligations. The district has limited funding and wants a quantitative evaluation comparing (a) purchasing and replacing medications before expiration, (b) training costs and refresher frequency, (c) expected reduction in morbidity/mortality using local incidence rates and response-time data, and (d) liability exposure under different implementation models (nurse-only vs. trained staff coverage). It also needs medical input on dosing, contraindications, storage conditions, and protocols for post-administration monitoring and EMS activation, including accommodations for students with disabilities and language access for guardians. Using the district’s provided incident statistics, budget constraints, and state-specific legal framework, recommend which policy option to adopt (including staffing model and consent approach) and specify the minimum compliant protocol and training plan the district should implement this school year.",232,250,482,226,246,0.003906
2025-12-13T17:49:39,63,resp_0184daf6cd3c165b00693d28a360c8819ab2dc2f90460f7796,gpt-5.2,"[Origin Task]:
A mid-sized U.S. city’s public school district is considering launching a pilot program that provides daily “as-needed” inhaler access and periodic spirometry screening for 2,400 middle-school students, after a rise in asthma-related ER visits and missed school days. The district’s legal counsel is concerned about compliance with state school-medication administration rules, FERPA/HIPAA boundaries for sharing health data with an outside pediatric pulmonology group, and liability exposure if a student has an adverse event during screening or inhaler use. The health team needs to define clinically appropriate inclusion/exclusion criteria, parental consent language, and emergency response protocols consistent with standard asthma care and pediatric safety guidelines. The finance office requires a quantitative cost–benefit model estimating program costs (staff time, equipment, training, medication stock, vendor contract) versus expected savings (reduced ER visits, reduced absenteeism funding loss, avoided substitute-teacher costs), including sensitivity analysis under different asthma prevalence and utilization assumptions. As the district’s consultant, draft a single integrated recommendation that determines whether to proceed, under what compliance and clinical safeguards, and with what budget and measurable success metrics for the 12‑month pilot.",232,245,477,226,241,0.003836
2025-12-13T17:49:44,64,resp_080a177624a73f7e00693d28a8e72481989f20b7938fe39c4f,gpt-5.2,"[Origin Task]:
A U.S. public school district is considering launching an opt-in telehealth program for students with asthma and ADHD, using a vendor that provides video visits plus an AI model that flags medication nonadherence and potential symptom escalation from nurse notes and attendance records. The district must decide whether the program can legally and ethically operate under HIPAA/FERPA and applicable state minor-consent and mandatory-reporting rules, while ensuring appropriate clinical oversight, documentation standards, and safeguards for false positives/negatives that could delay care. Using the pilot data (2,400 eligible students; projected 35% enrollment; baseline ER visit rate for asthma 0.18/student-year; expected reduction 22%; AI sensitivity 0.84 and specificity 0.91 for escalation alerts; $48 per enrolled student per month vendor fee; average ER claim cost $1,900; average parent work-loss cost $160 per ER visit; district budget cap $520,000/year), the superintendent needs an evidence-based recommendation on whether to proceed, modify, or reject the contract. Provide a decision memo that quantifies expected annual costs and savings, estimates net benefit under best/base/worst-case assumptions, and states the minimum contractual, consent, privacy, and clinical-governance provisions required for compliance and student safety.",232,267,499,226,263,0.004144
2025-12-13T17:49:50,65,resp_091b0029d0ec401b00693d28aed4748199800651a425016c84,gpt-5.2,"[Origin Task]:
A U.S.-based hospital system is considering deploying a machine-learning sepsis early-warning tool across its emergency departments and wants to use retrospective EHR data plus ongoing real-time monitoring, including sending text alerts to on-call clinicians’ personal phones. The compliance team is concerned about HIPAA Privacy/Security Rule obligations, state medical record and patient-notification laws, and FDA “software as a medical device” risk if the tool influences clinical decisions, while clinicians want to quantify expected patient benefit and harm (e.g., false alarms leading to unnecessary antibiotics and C. difficile risk) and finance wants a budget impact estimate. Using last year’s ED data (sepsis prevalence, baseline mortality, average time-to-antibiotics, ICU admission rate, and antibiotic adverse event rate) and the vendor’s reported sensitivity/specificity, the system needs a quantitative model of lives saved vs. complications caused, projected net cost (implementation, staffing, additional treatments, avoided ICU days), and a recommendation on whether to deploy, deploy with constraints (e.g., limited units, opt-in consent, human-in-the-loop), or postpone pending regulatory changes. Provide a go/no-go recommendation and the minimum compliant operational policy (data use, alerting workflow, documentation, and patient notice/consent approach) that satisfies applicable regulations while meeting clinical safety thresholds and a defined ROI target.",232,278,510,226,274,0.004298
2025-12-13T17:49:57,66,resp_0611eda98635b61500693d28b564d08195b7b3f7d8aaef7636,gpt-5.2,"[Origin Task]:
A U.S. county public health department is considering launching a mobile “test-and-treat” program that offers on-site rapid HIV testing and same-day initiation of PrEP for eligible adults, staffed by nurse practitioners and supported by a contracted telehealth physician for remote oversight. Using current CDC/USPSTF clinical eligibility guidance, state scope-of-practice rules for nurse practitioners, and federal privacy requirements (HIPAA plus 42 CFR Part 2 if substance-use treatment referrals are integrated), determine whether the proposed workflow and data-sharing with a community partner clinic is legally compliant and clinically safe, and specify any policy changes required (e.g., consent language, record segmentation, supervision, mandatory reporting). The department has a $2.4M annual budget and must decide between 2 vans operating 5 days/week or 3 vans operating 4 days/week; estimate expected new PrEP starts and HIV diagnoses averted over 12 months using provided assumptions: 28 clients screened per van-day, 6% HIV-positive rate among those tested, 32% PrEP-eligible among HIV-negative clients, 55% PrEP uptake when offered same-day, baseline annual HIV incidence 1.8% among PrEP-eligible clients without PrEP, PrEP reduces incidence by 92% with 70% adherence, and all-in cost per van-day is $6,000 (including labs and medication assistance navigation). Incorporate medical constraints (confirmatory testing, renal function screening timelines, follow-up scheduling) to assess feasibility and quantify how delays would change uptake and prevention impact. Deliver a recommendation on which operating model to choose and what compliance/clinical safeguards must be implemented before launch, supported by your calculations and legal/clinical rationale.",232,355,587,226,351,0.005376
2025-12-13T17:50:05,67,resp_0892b715a622e57c00693d28be13f4819096532d40cd93ce2a,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying an AI-supported “return-to-class” program after influenza/COVID-like outbreaks: students who report symptoms would be offered an on-site rapid test, and if positive, be sent home with a telehealth prescription option; aggregated results would be shared weekly with the county health department and a third-party analytics vendor. District leadership needs to decide whether to proceed and how to structure consent, data sharing, and staffing to comply with FERPA, HIPAA/telehealth rules, state minor-consent laws, and public-health reporting requirements while minimizing liability for missed diagnoses and ensuring equitable access for low-income families. Using last year’s attendance and outbreak data (assume 18,000 students, 8% symptomatic visits/week during peak 6 weeks, rapid test sensitivity 85%/specificity 98%, average absenteeism reduction of 0.7 days per true-positive correctly isolated, program cost $28 per test and $55 per telehealth visit with 35% positivity among symptomatic), estimate the expected net attendance-days saved and total program cost under two policy options: (A) test-all symptomatic students, (B) test-only those with fever plus one additional symptom, where this screen reduces testing volume by 40% but misses 25% of true positives. Recommend which option the district should adopt and specify the minimum compliant consent and data-sharing approach (including what can be shared with public health and the vendor) given the legal constraints and clinical safety considerations.",232,311,543,226,307,0.00476
2025-12-13T17:50:14,68,resp_00509ab5d1f11a6e00693d28c709048198b9e03b0533f3deff,gpt-5.2,"[Origin Task]:
A mid-sized U.S. manufacturing company with 1,200 employees is considering switching its health plan to a high-deductible option paired with an HSA and simultaneously launching an optional on-site hypertension/diabetes screening program run by a third-party clinic that would provide the employer only aggregated risk reports. In the last year the company had 9 medical emergencies on the factory floor and wants to reduce incidents, but the union is concerned about medical privacy, discrimination risk, and whether incentives (premium discounts and paid time to attend screenings) would be lawful. Using applicable U.S. legal/regulatory constraints (e.g., HIPAA privacy rules, ADA/GINA wellness-program limits, and OSHA general duty considerations), medical guidance on screening frequency and follow-up care, and quantitative analysis of projected costs and benefits (expected reduction in emergency events, changes in claims spending, incentive costs, and productivity impacts), determine whether the company should implement the program and, if so, what incentive design and data-sharing terms should be adopted. Provide a recommendation memo to the CFO and HR Director that includes the estimated annual net financial impact under at least two plausible scenarios and a compliance-ready policy outline the company can hand to the vendor and the union.",232,253,485,226,249,0.003948
2025-12-13T17:50:20,69,resp_00f43ba357ed3c6900693d28ccebcc8194957ddf5617e558d1,gpt-5.2,"[Origin Task]:  
A U.S.-based employer with 800 employees plans to introduce an on-site, nurse-run program offering annual influenza vaccines and optional rapid A1C screening for diabetes risk, and it also wants to offer a $300 premium discount to employees who participate. Leadership needs to ensure the program complies with HIPAA (including whether the employer or its vendor becomes a covered entity/business associate), the ADA and GINA limits on disability-related inquiries and genetic information, and the ACA wellness-program incentive rules (including maximum incentive percentages and “reasonable alternative standard” requirements). Using the company’s benefits data (current annual premium is $6,800 individual / $19,500 family; 55% enroll family; expected participation 60%; expected flu vaccination reduces sick days by 0.4 days per participant; A1C screening identifies 6% with prediabetes and reduces diabetes incidence by 1.2% over 3 years with an average avoided medical cost of $9,400 per case; average daily wage cost $310; program cost $95 per participant for vaccine and $38 for A1C; vendor fee $40,000/year), quantify the 3-year ROI under conservative and optimistic assumptions and determine the maximum legally compliant incentive design. Provide a recommendation on whether to proceed, what data flows/consents to require, and the final incentive structure and communication language the company should use to minimize regulatory and clinical risk while meeting the ROI target of at least 1.2x over three years.",232,311,543,226,307,0.00476
2025-12-13T17:50:28,70,resp_038e81c279b47f5b00693d28d46ae8819081d8b70da5f4f876,gpt-5.2,"[Origin Task]:
A U.S.-based home healthcare company is considering rolling out a remote patient monitoring (RPM) program for 500 Medicare patients with congestive heart failure using Bluetooth scales and blood-pressure cuffs, with data reviewed by nurses and escalated to physicians when thresholds are crossed. The company must decide whether to launch in California and Texas next quarter, balancing HIPAA and state privacy/telehealth requirements (including patient consent, data-sharing with device vendors, breach notification duties, and scope-of-practice constraints on nurse triage) against clinical safety obligations for timely intervention. Using provided assumptions—device+connectivity cost $65/patient/month, nurse monitoring time averages 12 minutes/patient/week at $42/hour loaded, expected hospitalization rate drops from 0.18 to 0.13 admissions/patient/quarter, average allowed amount per hospitalization is $14,500, and the program is expected to increase medication-related adverse events by 0.4% absolute due to more frequent titration—quantify the net financial impact over two quarters, estimate the expected change in serious adverse events, and identify whether any regulatory constraints materially alter the operating model (e.g., requiring physician-only review or stricter consent flows) such that costs or staffing assumptions must change. Based on this combined legal, clinical, and quantitative assessment, deliver a go/no-go recommendation and specify the minimum compliant policy and staffing configuration needed to launch.",232,290,522,226,286,0.004466
2025-12-13T17:50:36,71,resp_0bc67ea2b67da84000693d28dc2d048198a4ca2a0fa278e006,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is partnering with a pharmacy benefits manager to launch a 12‑month weight‑management program that includes prescribing GLP‑1 medications via telehealth to adults in three states (California, Texas, and New York), and the board needs to decide whether to proceed and how to price the program. Using expected enrollment (2,400 patients), baseline BMI distribution, projected average weight loss, adverse-event rates, and medication discontinuation probabilities, estimate the program’s net clinical impact (e.g., reduction in diabetes incidence proxies) and net financial impact (drug acquisition costs, staffing, monitoring labs, expected ER visits from side effects, and downstream savings) under three pricing models (monthly fee, outcomes-based rebate, and employer-sponsored bundle). Ensure the plan complies with key legal/regulatory constraints (telehealth prescribing rules for controlled/non-controlled substances, state scope-of-practice limits, HIPAA/42 CFR Part 2 where applicable, and anti-kickback/Stark considerations for PBM arrangements) and incorporates medically appropriate eligibility, monitoring, and contraindication policies aligned with standard of care. Provide a go/no-go recommendation and a defensible pricing and compliance approach the board can adopt now, including the quantitative assumptions you used and sensitivity ranges for the most uncertain parameters.",232,267,499,226,263,0.004144
2025-12-13T17:50:43,72,resp_0ad4f914d19273f700693d28e37cf48199b9ef3cff6bcf507c,gpt-5.2,"[Origin Task]:
A county jail healthcare contractor in the U.S. is considering switching from in-person physician visits to a hybrid telemedicine program for inmates with opioid use disorder, diabetes, and hypertension, after a spike in overdoses and two recent lawsuits alleging inadequate medical care. The jail must decide whether the new model complies with applicable constitutional standards for detainee medical care, state telehealth prescribing rules (including controlled substances), and federal privacy requirements for health information, while also ensuring clinical safety and continuity of care. Using last year’s data (average daily population 1,200; 18% diagnosed OUD; 9% diabetes; 22% hypertension; current overdose rate 14 per 1,000 inmate-months; projected reduction with hybrid program 25–40%; program cost $1.8M/year vs. current $1.4M/year; average hospitalization cost $9,500; estimated avoidable hospitalizations 160/year if adherence improves by 10–15%), quantify expected net cost impact and health outcome changes under conservative and optimistic assumptions. The jail’s insurer will only renew coverage if the contractor demonstrates that staffing, clinical protocols, and documentation meet recognized correctional healthcare standards and reduce liability exposure. Prepare a recommendation to the county board on whether to adopt the hybrid program, specifying the minimum legal/clinical safeguards and the quantitative threshold at which the program becomes cost-neutral or cost-saving.",232,287,519,226,283,0.004424
2025-12-13T17:50:50,73,resp_00ed56c13ea56e7d00693d28ea56d481949651854417f6bacd,gpt-5.2,"[Origin Task]:
A U.S. county public hospital system is considering launching a pharmacist-led hypertension telehealth program for low-income patients, where patients receive mailed home BP cuffs and a monthly medication review via video, with automated SMS reminders. After a recent incident in which a patient’s spouse used their cuff and the readings were mistakenly attributed to the patient, the system must decide whether to proceed and under what safeguards, while complying with HIPAA, state telehealth prescribing rules, and Medicare/Medicaid billing requirements for remote patient monitoring and chronic care management. Using last year’s claims data (12,000 eligible patients; baseline annual stroke/MI hospitalization rate 3.2%; average cost per hospitalization $38,000; expected program enrollment 35%; expected relative reduction in events 12–18%; device + shipping $55 per enrolled patient; staffing cost $42 per patient-month; expected monthly dropout 4%), estimate the net annual budget impact and cost per hospitalization averted under conservative and optimistic assumptions, and assess the legal/clinical risks of identity misattribution and medication changes without in-person vitals. Provide a recommendation on whether to implement, delay, or redesign the program, including the minimum compliance and patient-safety controls required before launch.",232,254,486,226,250,0.003962
2025-12-13T17:50:56,74,resp_0162bf69afd8831100693d28f0be248199956eb55383d47397,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district plans to install reusable water bottle filling stations and is considering adding an on-site fluoride dosing system to reduce dental caries, but several parents report children with chronic kidney disease and one with a history of fluoride sensitivity. The superintendent needs an analysis that balances public-health benefits and clinical contraindications, while complying with state drinking-water rules, FDA/CDC guidance, and relevant disability accommodation obligations for medically vulnerable students. Using district enrollment and health-office prevalence estimates, local baseline water fluoride levels from recent lab reports, and published caries-reduction and fluorosis risk data, quantify expected annual dental-treatment cost savings versus projected adverse-event/mitigation costs under three options: no change, fluoridate to 0.7 mg/L, or provide fluoride-free alternative access points plus targeted dental varnish. Produce a decision memo recommending one option, including the compliance plan, consent/notification approach, and the quantitative justification for the board vote next month.",232,202,434,226,198,0.003234
2025-12-13T17:51:01,75,resp_0abea9a31b3d356a00693d28f575bc8195aeb50445213a152c,gpt-5.2,"[Origin Task]:
A U.S.-based public school district is considering deploying an AI system that scans students’ faces at classroom entry and, when it detects a fever or concerning symptoms, automatically notifies parents and the school nurse, logs the event in a cloud dashboard, and temporarily restricts the student from attending extracurricular activities until medically cleared. The district must decide whether to proceed and, if so, what minimum set of policies and technical controls are required to comply with applicable student privacy and health-information rules (e.g., FERPA and any relevant state biometric/privacy laws), while also meeting practical clinical safety standards for fever screening and avoiding discriminatory impact. Using the vendor’s stated sensitivity/specificity, local disease prevalence, and the school’s daily attendance counts, estimate expected true/false positives and negatives per week and quantify operational consequences (nurse workload hours, parent notification volume, missed class time, and projected costs), including a comparison to manual nurse-led screening. Based on these legal, medical, and quantitative findings, deliver a recommendation to the superintendent on whether to deploy, pilot with constraints, or reject the system, and specify the required consent/notice language, data retention limits, escalation protocol, and monitoring metrics if it proceeds.",232,250,482,226,246,0.003906
2025-12-13T17:51:13,76,resp_09241863737773a800693d29019868819a88bf9f6104006bda,gpt-5.2,"[Origin Task]:
A U.S. county public school district is considering a policy to install classroom air purifiers and introduce an “opt-in” rapid COVID/flu testing program for students during respiratory season after a spike in asthma-related absences and two local outbreaks. The superintendent needs a recommendation that balances student health impacts (including asthma triggers, false positives/negatives, and isolation guidance), legal/regulatory constraints (FERPA privacy for test results, ADA accommodations for medically vulnerable students, and state public-health reporting requirements), and a quantitative cost–benefit analysis using the district’s data (attendance loss costs, nurse staffing hours, device procurement/maintenance, and expected reduction in missed days under different uptake rates). Use these inputs: 18,000 students, average daily attendance funding of $62 per student-day, current respiratory-season absence rate 8.5% for 14 weeks, estimated purifier program cost $1.35M upfront + $180k/year filters, testing program cost $7.80 per test with expected participation 35–65% weekly, and published estimates suggesting purifiers reduce respiratory-related absences by 8–18% relative and testing reduces outbreak-driven absences by 10–25% relative but adds 0.4 nurse hours per 100 tests. Produce a single policy recommendation (adopt, pilot, or reject; and under what conditions) that includes the projected net fiscal impact over one school year, compliance safeguards, and the minimum participation/efficacy thresholds needed for the program to break even.",232,314,546,226,310,0.004802
2025-12-13T17:51:19,77,resp_0cbf6d7ffca412a700693d2907c88c8198b9373824d5f45603,gpt-5.2,"[Origin Task]:
A regional hospital system plans to deploy an AI-assisted sepsis triage tool in its emergency departments that flags high-risk patients and automatically queues “standing order” labs and fluids before physician review, but clinicians worry about missed atypical presentations and lawyers warn about liability and compliance under EMTALA, CMS Conditions of Participation, HIPAA, and state informed-consent/medical-practice rules. The system has 12 months of retrospective ED data (adult visits, outcomes, timestamps, vitals/labs) showing sepsis prevalence of 2.1%, and the vendor reports model performance at two adjustable thresholds: Threshold A (sensitivity 0.91, specificity 0.82) and Threshold B (sensitivity 0.80, specificity 0.92); the CFO needs an estimate of annual net impact given 220,000 adult ED visits/year, $180 average cost per auto-queued lab bundle, $35 per fluid kit, an expected 65% of flagged cases receiving both, an estimated $14,000 average incremental cost of a missed sepsis case, and a projected 18% relative reduction in mortality for true-positive cases treated ≥45 minutes earlier. Draft a recommendation memo determining whether to deploy and which threshold to use, including (i) quantitative estimates of false positives/negatives, expected cost and harm tradeoffs, and sensitivity analysis for prevalence ±0.5%, (ii) clinical governance safeguards to prevent unsafe automation and ensure clinician override, and (iii) a compliance and risk posture describing how to implement with appropriate patient notice/consent, documentation, auditability, and incident response under the cited regulations.",232,337,569,226,333,0.005124
2025-12-13T17:51:27,78,resp_0f6d79db6f690df300693d290f4e908195bbf74966346cb6ea,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying an AI-enabled smartphone app that uses student self-reports and wearable data (heart rate and sleep) to flag elevated suicide-risk and automatically route alerts to school nurses and an on-call telepsychiatry vendor. The district needs to determine whether the planned data flows and alerting procedures comply with applicable privacy and consent rules (e.g., FERPA for education records, HIPAA where the telehealth provider is involved, and relevant state minor-consent/mandatory-reporting requirements), while also assessing clinical safety risks such as false positives/negatives, appropriate thresholds, and protocols for urgent evaluation. Using last year’s anonymized baseline data (12,000 students; ~2% annual incidence of reported suicidal ideation; vendor-claimed sensitivity 82% and specificity 91%), estimate expected monthly alert volume, positive predictive value, staffing hours needed for nurse follow-up (assume 20 minutes per alert plus 60 minutes for each true positive requiring parent/guardian contact), and budget impact against a $250,000 annual cap. Produce a go/no-go recommendation and, if proceeding, specify the minimum compliant consent language and operational policy changes (escalation pathways, record retention, and vendor contract clauses) required before launch in the next semester.",232,269,501,226,265,0.004172
2025-12-13T17:51:33,79,resp_0aaebceec194c7f900693d2915c36481998823fae8fd764800,gpt-5.2,"[Origin Task]:
A county public school district in California is considering launching a voluntary influenza + COVID-19 vaccination clinic on campus for students aged 12–17, using a contracted mobile healthcare provider, and wants to collect proof of vaccination plus basic health screening data to manage clinic throughput and follow-up. District leadership is concerned about compliance with HIPAA (provider records), FERPA (student education records), California minor consent and parental notification rules, and disability accommodation requirements for students with medical contraindications, while also needing to choose between an “opt-in with scheduled appointments” model and an “opt-out with default time slots” model. Using projected participation rates from last year (38% for flu, 22% for COVID-19) and a new survey indicating an additional 15% of families would participate if clinics are held during parent-teacher conference week, estimate staffing, time slots, and expected cost per vaccinated student under two staffing options (2 nurses vs 4 nurses) given each vaccination encounter averages 9 minutes plus 3 minutes documentation and the vendor charges $140/hour per nurse with a 4-hour minimum per day. Draft a policy recommendation that selects the clinic model and data-handling approach, quantifies operational feasibility and budget impact, and specifies the legally compliant consent, documentation retention, and accommodation procedures the district should adopt before implementation.",232,274,506,226,270,0.004242
2025-12-13T17:51:39,80,resp_0715234c18c7993100693d291bc3e48194852bb13dd2d7d55f,gpt-5.2,"[Origin Task]:
A mid-sized U.S. public school district is considering launching an on-campus seasonal influenza vaccination program for students ages 12–17 using a contracted pharmacy chain, offering an opt-in clinic during school hours and storing limited vaccine supply in portable medical refrigerators. The superintendent needs a recommendation that balances medical safety (contraindications, emergency response capacity for rare anaphylaxis, infection control, and appropriate documentation), legal/regulatory compliance (HIPAA vs FERPA handling of student health records, state minor-consent rules and parental permission requirements, pharmacy scope-of-practice and standing orders, and liability/indemnification terms), and quantitative feasibility (forecast demand, staffing needs, cold-chain capacity, and a cost–benefit estimate comparing program costs against expected reductions in absenteeism and substitute-teacher expenses). Use provided district data (student counts by school, prior-year absenteeism by month, vaccine and staffing quotes, and local flu incidence) to compute expected uptake, total program cost, and break-even point under conservative and optimistic scenarios. Based on these analyses, deliver a go/no-go decision and the minimum compliance and clinical safeguards the district must implement before proceeding.",232,238,470,226,234,0.003738
2025-12-13T17:51:45,81,resp_0078a6ed5a86ef7000693d29213ca4819981a3a277bcfa7b7a,gpt-5.2,"[Origin Task]:
A regional hospital system is considering launching an AI-assisted medication-reconciliation and discharge-planning program for older adults with heart failure and diabetes, which would pull data from its EHR, local pharmacy fill records, and a contracted home-health provider to reduce 30-day readmissions. Leadership needs to determine whether the proposed data-sharing, patient consent workflow, and vendor contracting approach complies with HIPAA and applicable state privacy laws, and whether the clinical protocol meets standard-of-care expectations for medication safety and follow-up. Using last year’s discharge volume, baseline readmission rate, expected effect size from peer-reviewed studies, program costs (software licensing, staffing, and training), and payer penalties/bonuses, estimate the break-even point and projected net financial impact under conservative and optimistic assumptions, including sensitivity to uptake and false-alert rates. Also assess patient-safety risks (e.g., anticoagulants, insulin dosing, renal impairment) and propose measurable clinical guardrails and monitoring metrics that would satisfy hospital quality committees and regulators. Deliver a single recommendation on whether to proceed, modify, or pause the rollout, specifying the minimum compliance changes and the quantitative thresholds (ROI and safety metrics) that must be met before system-wide deployment.",232,249,481,226,245,0.003892
2025-12-13T17:51:50,82,resp_0a29962fe024ecfa00693d2926b5188195879cce5e2e62e361,gpt-5.2,"[Origin Task]:
A U.S.-based telehealth company that provides remote diabetes management wants to launch an AI-driven insulin titration feature for adult patients in California and Texas, using continuous glucose monitor (CGM) data and patient-reported meals/insulin doses, and plans to store the data with a third-party cloud vendor that also performs model monitoring. After a recent near-miss hypoglycemia incident, the company must decide whether to deploy the feature as “clinical decision support” requiring clinician sign-off, or as an automated recommendation tool sent directly to patients, while ensuring compliance with HIPAA, relevant state privacy laws, and FDA considerations for software as a medical device. The company also needs to quantify safety and effectiveness by estimating expected changes in hypoglycemia rate and HbA1c based on pilot data (including confidence intervals and a risk-benefit threshold set by its medical director), and to model how different alert thresholds impact false alarms, clinician workload, and patient adherence. Draft a go/no-go recommendation memo to the executive team that (1) selects the deployment model, (2) specifies the minimum compliance controls and contractual clauses needed with the cloud vendor, and (3) justifies the decision using the quantitative analysis of patient safety outcomes and operational capacity constraints.",232,259,491,226,255,0.004032
2025-12-13T17:51:56,83,resp_0a212a838595df2900693d292c5230819bacb25282fdc3171c,gpt-5.2,"[Origin Task]:
A mid-sized U.S. hospital system is considering launching a “hospital-at-home” program for Medicare and commercially insured patients with mild-to-moderate congestive heart failure exacerbations, using remote monitoring devices and a contracted nurse practitioner team to deliver in-home IV diuretics and daily telehealth check-ins. Leadership needs to ensure the clinical eligibility criteria and escalation pathways are medically safe, while also complying with federal and state requirements for telehealth, scope-of-practice, prescribing/administration of IV medications in the home, HIPAA/security obligations for device data, and any Medicare conditions of payment that apply. Finance has provided projections that 320 patients/year would be eligible, average length of acute episode is 4.2 days, expected 30-day readmission rate is 14% under hospital-at-home vs 18% under inpatient, device+staffing cost is $430/day per patient, and the avoided inpatient variable cost is estimated at $1,050/day (but inpatient DRG reimbursement would drop by $2,800 per episode if shifted out of inpatient status). Create a recommendation on whether to proceed, including quantified net annual financial impact under at least two plausible adoption scenarios, the minimum safe staffing ratios needed based on the episode volume assumptions, and the key legal/regulatory constraints that must be satisfied before go-live.",232,275,507,226,271,0.004256
2025-12-13T17:52:05,84,resp_0ed9bf098f5b0dc600693d2935ce048194ae85b82db4b6a4fd,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is considering launching an AI-assisted telehealth program for patients with Type 2 diabetes that uses at-home glucose meters and monthly virtual visits, and it plans to market the service in California, Texas, and Florida while contracting with a third-party cloud vendor to store patient data and transmit readings to clinicians. Recent adverse events at a competitor raised concerns about delayed hypoglycemia detection, so leadership needs to quantify clinical risk (expected event rates, sensitivity/specificity tradeoffs, and staffing response-time impacts) and compare it to projected cost savings and reimbursement revenue under current payer rules. The program must also comply with HIPAA/HITECH and relevant state privacy/telemedicine requirements (including consent, data sharing, breach notification, and cross-state licensure rules), and the hospital’s medical director wants a defensible medical protocol for triage thresholds and escalation to in-person care. Using these constraints, decide whether to launch, and if so, specify the maximum patient enrollment, minimum staffing levels, and data-governance/consent approach that keeps the program legally compliant and clinically safe while meeting a target operating margin of at least 8% in year one.",232,246,478,226,242,0.00385
2025-12-13T17:52:11,85,resp_0c0db38c9c3be5bd00693d293bfc488196bf8dbe7249d4194b,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is considering launching a pharmacist-led remote hypertension program that uses mailed blood-pressure cuffs and a smartphone app to adjust medications between office visits, and it wants to expand enrollment to nearby rural counties, including patients who may be pregnant or have chronic kidney disease. The system must decide whether the program design and consent language comply with HIPAA (data sharing with the app vendor), state telehealth and remote patient monitoring rules (licensure, prescribing, and supervision), and FDA/FTC requirements for the device/app claims, while ensuring the clinical protocol aligns with current standards of care and contraindications. Using projected enrollment of 2,500 patients, baseline uncontrolled hypertension rate of 62%, expected absolute control improvement of 12–18 percentage points, an average program cost of $38 per patient per month, and an estimated avoided-stroke rate of 0.9–1.4 per 100 patient-years with $27,000 average net cost per stroke, quantify the expected 12‑month budget impact and break-even conditions under conservative, base, and optimistic assumptions. Recommend whether to proceed, what minimum risk controls and exclusions are necessary, and what key contractual/regulatory provisions must be added before launch.",232,254,486,226,250,0.003962
2025-12-13T17:52:19,86,resp_0765cb84c234c45f00693d2943832c81998fb8fe3ff4296eb2,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying an AI-driven mental-health screening program for students (ages 12–18) that flags elevated depression/suicide-risk based on short weekly questionnaires and optional wearable sleep data, with referrals routed to school counselors and a partnered pediatric telehealth clinic. District leadership must determine whether the program can be implemented lawfully under FERPA, HIPAA (where applicable), state minor-consent and mandatory reporting laws, and accessibility/non-discrimination requirements (e.g., ADA/Section 504), while also ensuring clinically appropriate triage thresholds and escalation protocols to avoid harm from false positives/negatives. Using last year’s data (10,000 students; estimated 6% clinically significant depression prevalence; screening sensitivity 0.82, specificity 0.93; counselor capacity 180 new appointments/week; telehealth capacity 60/week; expected 70% student participation; projected $420,000 annual program cost; estimated $1,800 average downstream cost per untreated severe case; and a proposed 48-hour response SLA for high-risk flags), evaluate whether the program is operationally feasible and cost-justified and what minimum policy safeguards (consent flow, data retention, incident response, and referral criteria) are required to meet legal and medical standards. Provide a go/no-go recommendation and, if go, specify the single screening threshold and referral routing rule that meets capacity constraints while minimizing expected harm and compliance risk.",232,300,532,226,296,0.004606
2025-12-13T17:52:26,87,resp_0885654cb32bda3c00693d294a2e88819aab1bc94a64777c48,gpt-5.2,"[Origin Task]:
A county public hospital is considering launching an employer-sponsored “return-to-work after illness” program for its 1,200 unionized staff that would use wearable temperature/heart-rate sensors plus a nurse-led telehealth check-in to reduce influenza/COVID-19 sick days, but the union and compliance office are concerned about whether the data collection and employment decisions could violate HIPAA, the ADA, and state employee-privacy laws. Using clinical guidance on infectious disease transmission and fitness-for-duty, propose a medically appropriate screening and clearance policy (including what metrics, thresholds, and follow-up actions are clinically justified) while ensuring the policy’s data handling, consent, accommodations, and anti-discrimination safeguards are legally defensible. Quantitatively model the expected impact on staffing and cost over one flu season by comparing (a) status quo vs (b) the proposed program, incorporating sensor false-positive/false-negative rates, baseline absenteeism, replacement staffing costs, and the risk/cost of workplace outbreaks. Deliver a recommendation on whether to proceed and, if so, the minimum viable policy design that achieves a target of at least a 10% reduction in sick-day costs without increasing legal exposure beyond a defined low-risk threshold.",232,250,482,226,246,0.003906
2025-12-13T17:52:33,88,resp_058fca09085058dc00693d29512e5c819bb846fe4fda201e34,gpt-5.2,"[Origin Task]:  
A regional hospital system plans to launch an AI-assisted telehealth program for post-discharge heart failure patients in California and New York that collects daily weight, blood pressure, symptom surveys, and wearable heart-rate data, and shares alerts with clinicians and (with patient permission) a contracted home-health agency. Leadership needs to determine whether the program’s data flows, consent language, and vendor contracts comply with HIPAA (including business associate requirements), applicable state privacy rules, and medical device/software obligations, while also ensuring clinical safety (e.g., avoiding missed decompensation and minimizing false alarms) and operational feasibility. Using last year’s data (8,000 eligible discharges; 22% 30-day readmission rate; average readmission cost $14,500; proposed program cost $95 per patient-month; expected enrollment 60%; expected effect 18% relative reduction in readmissions; alert algorithm sensitivity 0.82 and specificity 0.74 with nurse review capacity capped at 120 alerts/day), the hospital must quantify expected net financial impact, staffing needs, and patient risk tradeoffs under different enrollment and alert-threshold policies. Draft a board-ready recommendation on whether to proceed and under what compliance posture, clinical governance safeguards, and quantitative go/no-go thresholds (ROI, maximum alert volume, and minimum clinical benefit) the program should be approved.",232,279,511,226,275,0.004312
2025-12-13T17:52:39,89,resp_05d901e32e2ae8a300693d2957206c8199b49574fd0edc1835,gpt-5.2,"[Origin Task]:
A U.S.-based school district is considering adopting an AI-enabled smartphone app that screens students ages 13–18 for depression risk using weekly questionnaires and passive sensor data, automatically alerting a contracted telehealth clinic when a student crosses a risk threshold. The district must decide whether to deploy the program across 10,000 students and needs an analysis that combines medical appropriateness (screening accuracy, false positives/negatives, crisis response standards), legal/regulatory compliance (FERPA, HIPAA applicability, state minor-consent and mandatory reporting rules, and data-sharing/retention requirements), and quantitative evaluation (expected number of alerts per week given stated sensitivity/specificity and base rates, staffing needs and response-time capacity, and cost-effectiveness versus current counseling resources). The vendor proposes 92% sensitivity and 88% specificity, a 6% annual prevalence of major depression in this age group, and a service model where one clinician can handle 18 alerts/day with a 24-hour follow-up SLA; the district has a $750,000 annual budget and requires that no student data be sold or used for advertising. Produce a recommendation on whether and how the district should implement the program, including the minimum contract terms and operational safeguards required to meet medical standards and legal obligations while staying within budget and staffing constraints.",232,272,504,226,268,0.004214
2025-12-13T17:52:44,90,resp_07b85941791b95c500693d295d1cc08197b7972a76cda61d3f,gpt-5.2,"[Origin Task]:
A U.S.-based public school district is considering contracting with a telehealth provider to offer ADHD evaluations and stimulant-prescription management for students ages 10–17, with visits conducted on school premises and parents joining remotely, while the vendor proposes storing visit recordings and sharing de-identified data for research. The district’s counsel and medical advisory board need to determine compliance with HIPAA/FERPA, state minor-consent and telemedicine rules, controlled-substance prescribing requirements (including any applicable federal rules), and mandatory reporting obligations if clinicians identify abuse or self-harm risk. Finance leaders also need a quantitative cost–benefit and risk analysis comparing the program to the current referral model, including projected utilization, no-show rates, clinician capacity limits, expected changes in absenteeism/academic performance, and sensitivity analysis for adverse-event probability and potential liability/settlement ranges. Produce a recommendation memo on whether to proceed, what contract terms and clinical safeguards are required, and an implementation plan that meets legal requirements while minimizing medical risk and staying within a fixed annual budget cap.",232,219,451,226,215,0.003472
2025-12-13T17:52:50,91,resp_0f1ef9eed4a5331a00693d2962be6c81998d70c710404fd75a,gpt-5.2,"[Origin Task]:
A mid-sized U.S. manufacturing company with 1,200 employees plans to introduce an on-site clinic that will provide flu/COVID boosters and a new RSV vaccine for eligible workers, plus a voluntary biometric screening (blood pressure, A1c, cholesterol) with a $300 annual premium discount for participants, and management wants to use aggregated results to target wellness interventions by department. The company operates in California and Texas, uses a third-party clinic vendor, and is concerned about compliance with HIPAA (including business associate obligations), the ADA/GINA rules for “voluntary” wellness programs, and state privacy laws (including California’s CPRA), while also needing to minimize medical risk (contraindications, adverse event response, and emergency readiness) and ensure equitable access for shift workers. Using expected uptake rates by age group, vaccine and screening unit costs, projected reductions in sick days, and the premium-discount budget impact, determine whether the program is cost-effective over 12 months and what participation threshold makes it break even, while identifying the legally necessary consent, data-minimization, and reporting design to avoid employment discrimination and privacy violations. Provide a recommendation to the CFO and HR Director on whether to launch as proposed, modify the incentive structure and data flows, or cancel, including the final go/no-go decision and the key compliance and clinical safeguards required.",232,280,512,226,276,0.004326
2025-12-13T17:52:57,92,resp_04d3006aece97b6600693d2969cc1081959ebbf1ec8051baec,gpt-5.2,"[Origin Task]:
A mid-sized U.S. hospital system plans to launch an employer-facing “back-to-work” program that offers same-day telehealth visits for respiratory symptoms, optional rapid flu/COVID testing at onsite kiosks, and a standardized “fitness-for-duty” letter to speed employee return, while the employer requests weekly de-identified dashboards and occasional named confirmations for safety-sensitive roles. As the hospital’s consultant, evaluate whether the proposed data flows and letters comply with HIPAA, applicable state privacy rules, and employment/disability constraints (e.g., ADA/EEOC), and whether the clinical protocol meets an appropriate standard of care and patient safety for triage and work-clearance decisions. Quantitatively model expected outcomes over the first 6 months using the employer’s workforce size (12,000), historical respiratory-illness absence rate (1.8% weekly in peak season, 0.6% otherwise), test sensitivity/specificity assumptions, visit capacity (250/day), and program costs/reimbursement to estimate net financial impact and the probability of increased workplace transmission under different eligibility rules. Recommend whether to proceed, and if so, specify the minimum policy changes, consent language, reporting format, and clinical guardrails required before go-live.",232,255,487,226,251,0.003976
2025-12-13T17:53:04,93,resp_009ea6ec5068f19f00693d297050708194aa610581f5f350fe,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering a policy to install UV-C air disinfection units and upgrade ventilation in 25 aging school buildings to reduce respiratory infection spread, but the teachers’ union and parents are concerned about ozone exposure, asthma exacerbations, and student privacy if air-quality sensors collect occupancy data. Using current public-health evidence on UV-C/ventilation effectiveness and potential adverse effects, applicable regulations (e.g., OSHA workplace safety, EPA/state indoor air standards, FERPA implications for sensor data, and procurement/contracting requirements), and a quantitative cost–benefit/risk model that estimates infections avoided, asthma-related ER visits potentially induced/avoided, absenteeism savings, and total lifecycle costs under uncertainty, determine whether the district should proceed and under what constraints (technical specs, monitoring, consent/data handling, and maintenance). Assume a fixed capital budget of $8M, differing building sizes/airflow rates, and that the district must justify the decision in a public board meeting with transparent assumptions. Provide a final recommendation on whether to adopt the policy and the minimum compliant implementation conditions needed to proceed.",232,232,464,226,228,0.003654
2025-12-13T17:53:10,94,resp_0691d7dd90ab9f2300693d2976c7e48193ab0e3b6670861a96,gpt-5.2,"[Origin Task]:
A U.S. public school district is considering installing UV-C air disinfection units in 40 classrooms to reduce respiratory infections, but the teachers’ union has raised concerns about ozone exposure, skin/eye injury risk, and whether the district must treat the deployment as a workplace hazard subject to OSHA requirements and state public health regulations. The superintendent needs an analysis that integrates medical evidence on UV-C effectiveness and safety thresholds, legal/regulatory obligations (OSHA hazard communication, ventilation standards, and any state-specific indoor air quality rules), and a quantitative cost–benefit model comparing (a) UV-C units, (b) portable HEPA filtration, and (c) no new intervention. Using the district’s data (average 25 students + 1 teacher per classroom, 180 school days/year, current absenteeism 6% with 30% attributed to respiratory illness, substitute teacher cost $220/day, parental productivity loss valued at $160/day per absent student, and a pilot study suggesting UV-C reduces respiratory-related absences by 18% while HEPA reduces by 12%), determine whether the district should proceed and, if so, which option to select and what compliance and monitoring plan (e.g., exposure limits, signage/training, maintenance logs, incident reporting) must be included in the final board proposal.",232,272,504,226,268,0.004214
2025-12-13T17:53:17,95,resp_0b7db89dac2438be00693d297d2c9881988c781128ba63d6b5,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering launching a district-wide “screen-and-treat” program for adolescent depression and anxiety that uses a smartphone app to administer PHQ-9/GAD-7 screenings, flags at-risk students, and offers telehealth follow-ups plus optional parental notifications. Recent incidents include one student self-harm event and multiple parent complaints about privacy, while the district’s insurer requires evidence of clinical effectiveness and a quantified risk/benefit justification before underwriting the program. You must evaluate the program’s medical appropriateness (screening frequency, false-positive/false-negative implications, referral pathways, emergency escalation protocols), legal/regulatory compliance (FERPA, HIPAA where applicable, state minor-consent and mandatory reporting laws, data retention and vendor contracting requirements), and quantitative feasibility (expected prevalence rates, projected number of referrals, staffing capacity, per-student cost, and cost-effectiveness versus status quo using realistic assumptions and sensitivity ranges). The district also wants a defensible policy for when and how parents are notified and how to handle students who refuse consent, including documentation standards. Produce a board-ready recommendation on whether to proceed, what safeguards and contract terms are required, and a quantified estimate of operational load and budget impact for the first academic year.",232,260,492,226,256,0.004046
2025-12-13T17:53:22,96,resp_09658cc44532fc5a00693d2982defc819b8c030a860037b4aa,gpt-5.2,"[Origin Task]:
A county public hospital system plans to launch a 12‑month telehealth program that uses an AI triage chatbot for patients with diabetes and hypertension, and it must decide whether to deploy it in-house or through a third-party vendor that will host data on U.S.-based cloud servers. The hospital’s compliance team needs to ensure the program meets HIPAA requirements (including Business Associate Agreements, minimum necessary use, breach notification timelines) and state telemedicine and informed-consent rules, while the clinical leadership must verify that the chatbot’s escalation thresholds and contraindication prompts are safe for high-risk patients and do not delay urgent care. Finance has provided projections: 18,000 eligible patients, expected 35% enrollment, average 1.8 chatbot interactions per enrolled patient per month, vendor fee $0.42 per interaction plus $240,000 annual platform fee, in-house build cost $1.3M upfront plus $34,000/month operations, and an estimated reduction of 0.06 ED visits per enrolled patient-year (average avoided ED cost $1,450) but a potential 0.4% rate of missed escalations leading to adverse events (average liability and remediation cost $38,000 each). Using these facts, determine which option the hospital should choose and specify the key legal/compliance conditions and clinical safety guardrails that must be included in the final implementation decision.",232,287,519,226,283,0.004424
2025-12-13T17:53:29,97,resp_056dfd269490966600693d29893574819b826f5aad749b0c6f,gpt-5.2,"[Origin Task]:
A U.S.-based public school district plans to deploy an AI-driven screening program in 12 middle schools to flag students at risk for depression and self-harm using a short questionnaire plus optional wearable sleep/activity data, with alerts sent to school nurses and (in some cases) parents. The district must decide whether to run the program as an “opt-in” consent model or an “opt-out” model, while complying with FERPA, relevant state minor-consent and mandatory reporting rules, and avoiding practices that could be interpreted as providing unlicensed medical diagnosis or violating privacy/anti-discrimination requirements. Using pilot data (screening sensitivity 0.82, specificity 0.90; expected prevalence 6%; program cost $28 per student screened; follow-up clinical evaluation $160 per flagged student; nurse time 45 minutes per flagged student at $42/hour; projected enrollment 9,600 students; and an estimated 0.3% annual self-harm attempt rate with a 35% relative reduction among true positives who complete follow-up), quantify the expected annual budget impact, false-positive workload, and expected reduction in attempts under each consent model assuming opt-in participation is 45% and opt-out participation is 88%. Recommend which consent model to adopt and draft a compliant high-level policy position (one paragraph) that specifies data handling, parent/student notification, and escalation pathways consistent with the legal constraints and clinical safety obligations.",232,295,527,226,291,0.004536
2025-12-13T17:53:35,98,resp_0376ec0edc9715e800693d298f34848199b221245d5afb3aaf,gpt-5.2,"[Origin Task]:
A mid-sized U.S. city public school district is considering replacing sugary drinks in all vending machines with flavored electrolyte beverages marketed to teens, but several students have diabetes, kidney disease, and hypertension, and the district nurse has raised concerns about sodium, caffeine, and labeling. The district must ensure compliance with applicable federal and state rules (e.g., USDA “Smart Snacks in School” standards and any state nutrition regulations) and assess potential liability exposure if a student experiences an adverse health event on campus related to the new products. Using the product nutrition panels and ingredient lists, estimate the likely change in average daily sugar, sodium, and caffeine intake per student given projected sales volumes, and quantify expected impacts on high-risk subgroups (e.g., percent exceeding recommended limits) under reasonable assumptions. Based on this combined legal, medical, and quantitative assessment plus practical implementation constraints, produce a recommendation on whether to proceed, modify the product list (including thresholds or exclusions), or abandon the change, and specify the policy language the district should adopt for procurement and on-campus sales.",232,219,451,226,215,0.003472
2025-12-13T17:53:40,99,resp_020f54f86498942f00693d2994f5a08190978a9f69e0f25cd9,gpt-5.2,"[Origin Task]:
A U.S.-based hospital system plans to deploy an AI-driven remote patient monitoring program for recently discharged heart-failure patients in California and Texas, using wearable sensors that transmit heart rate, weight, and blood pressure to a centralized care team and trigger nurse outreach when risk scores exceed a threshold. After a pilot, leadership must decide whether to expand systemwide and set alert thresholds, staffing levels, and escalation pathways while ensuring compliance with HIPAA, applicable state privacy laws (including California’s), and FDA/FTC rules on medical-device software and marketing claims, plus clinician licensure/telehealth constraints across state lines. Using the pilot’s outcome data (30-day readmissions, emergency visits, mortality, false-alert rates, and nurse time per alert) and the proposed subscription/device costs, quantify the expected clinical benefit and net financial impact over 12 months under at least two threshold/staffing configurations, including sensitivity analysis for adherence drop-off and sensor error rates. Also assess patient-safety risks (alarm fatigue, missed detections, equity impacts for patients without reliable internet) and specify documentation/consent language and data-retention/sharing policies to reduce regulatory and malpractice exposure. Deliver a recommendation on whether to expand, which configuration to adopt, and the minimum compliance and clinical governance controls required before launch.",232,267,499,226,263,0.004144
2025-12-13T17:53:47,100,resp_0e84018ad1f50df000693d299b5a10819490cae196d8c70238,gpt-5.2,"[Origin Task]:
A mid-sized U.S. university is planning to deploy an AI-assisted telehealth program for students that uses wearable data (heart rate, sleep, activity) and in-app questionnaires to flag elevated suicide risk and automatically route urgent cases to on-call clinicians, with data stored in a cloud vendor and limited sharing with campus security during emergencies. After two recent incidents and parent pressure, leadership must decide whether to launch this semester and what minimum policy, consent language, and operational safeguards are required to reduce legal exposure while still meeting clinical duty-of-care expectations. Using applicable U.S. legal/regulatory constraints (e.g., HIPAA/FERPA applicability, state minor-consent and mandatory reporting rules, telehealth prescribing and licensure requirements, breach notification obligations) and medical standards for suicide-risk screening and escalation, quantify expected annual impact and risk by modeling sensitivity/specificity-driven false positives/negatives, staffing/response-time capacity, and projected costs (clinical labor, vendor fees, and liability exposure) under at least two deployment options. Incorporate common-sense operational realities (student behavior, after-hours coverage, emergency transport, and campus security involvement) to assess feasibility and unintended harms. Deliver a recommendation on whether to proceed now, delay, or redesign, and specify the required compliance posture and quantitative go/no-go thresholds the university should adopt before launch.",232,276,508,226,272,0.00427
2025-12-13T17:53:54,101,resp_07437ee363844cc500693d29a29ee08199895e2f05496b7c6c,gpt-5.2,"[Origin Task]:  
A U.S.-based food manufacturing company with 1,200 employees is considering launching an optional on-site health screening program that includes blood pressure checks, HbA1c testing, and a questionnaire about sleep and medication use, with $50 gift cards for participants and higher employer HSA contributions for those who complete follow-up coaching. Leadership wants to reduce health-plan costs and absenteeism, but must ensure the program complies with ADA/GINA, HIPAA privacy rules, and ACA wellness-program incentive limits, while also assessing clinical appropriateness and avoiding harm from false positives and unnecessary referrals. Using last year’s claims and absence data (including baseline prevalence estimates for hypertension and prediabetes), estimate the expected net financial impact over 24 months under two participation rates (35% and 60%), accounting for test sensitivity/specificity, downstream confirmatory visit costs, projected risk reduction from coaching, and administrative expenses. Also evaluate whether the proposed incentives could be viewed as coercive or discriminatory and recommend compliant modifications to consent, data handling, and incentive design. Prepare a board-ready memo recommending whether to proceed, under what revised program terms, and the quantitative break-even threshold for participation and risk reduction.",232,247,479,226,243,0.003864
2025-12-13T17:54:00,102,resp_07723722b4e33e6900693d29a8367c8198b277629f823502ad,gpt-5.2,"[Origin Task]:  
A U.S. public school district is considering installing UV-C air disinfection units in 30 classrooms after a spike in influenza and RSV cases, and must decide whether to proceed this semester or delay until summer break. Using published clinical/healthcare evidence on expected infection-risk reduction and contraindications (e.g., asthma exacerbation risk, ozone generation, and UV exposure safety), and ensuring compliance with applicable U.S. regulations and standards (e.g., OSHA indoor air guidance, EPA/UL safety standards for UV/ozone, state public procurement rules, and student privacy requirements when tracking illness-related absences), evaluate whether the program can be implemented without creating unacceptable health or legal risk. Perform a quantitative cost–benefit analysis that estimates expected avoided sick days, substitute-teacher costs, and potential liability/insurance premium impacts under at least two plausible infection-rate scenarios, incorporating uncertainty ranges and a break-even point per classroom. Based on the medical safety assessment, regulatory constraints, and the quantified financial outcomes, deliver a recommendation to the school board on whether to purchase, which unit specifications and monitoring policies to require, and what disclosures/consent processes (if any) should be adopted before deployment.",232,247,479,226,243,0.003864
2025-12-13T17:54:06,103,resp_0dd160028431064a00693d29aec4fc8194afdc061be7423e14,gpt-5.2,"[Origin Task]:
A U.S.-based school district is considering installing UV-C air disinfection units and upgrading HVAC filtration across 20 schools to reduce seasonal respiratory illness, but the teachers’ union is concerned about potential eye/skin exposure risks and the district’s legal team needs to ensure compliance with OSHA, state workplace-safety rules, and student privacy obligations if health metrics are tracked. The district has two vendor proposals with different UV-C intensities, shielding designs, maintenance schedules, and costs, and it has three years of absenteeism and nurse-visit data plus local influenza/COVID trends; it wants to estimate expected reductions in staff/student sick days and ER visits while accounting for uncertainty and equity impacts across schools with different ventilation baselines. Using medically grounded assumptions about UV-C effectiveness and exposure risk thresholds, quantify the cost-benefit (including avoided substitute-teacher costs and healthcare utilization), calculate the break-even point under best/expected/worst-case scenarios, and identify the minimum safety and monitoring requirements needed to stay compliant with applicable regulations. Provide a recommendation on whether to proceed, which proposal to choose (or whether to pilot first), and what policy language and consent/notice processes the district should adopt before deployment.",232,246,478,226,242,0.00385
2025-12-13T17:54:13,104,resp_004e4efd3cd4e86900693d29b59e00819ba17c1b91cae5dda6,gpt-5.2,"[Origin Task]:
A U.S.-based hospital system operating in California and Texas plans to deploy an AI-driven remote patient monitoring program for 5,000 Medicare patients with heart failure using Bluetooth scales and blood-pressure cuffs, with a third-party vendor hosting data in the cloud and nurses making medication-titration calls based on alerts. Leadership must decide whether the projected reduction in 30-day readmissions (from 18% to 14%) justifies the program cost ($220 per patient-month plus $600,000 fixed implementation) given expected adverse-event rates from false negatives (0.3% per month leading to ER visits) and false positives (6% per month causing unnecessary visits), and whether staffing levels meet clinical safety standards. The program must comply with HIPAA, state privacy rules (including California’s CPRA), FDA/FTC considerations for clinical decision support marketing, and Medicare billing requirements for RPM/CCM, including documentation and patient consent constraints across both states. Using the provided figures and any necessary reasonable assumptions, produce a recommendation to the board on whether to launch, modify, or delay the program, including a quantified cost–benefit/ROI and risk exposure estimate and a compliance posture summary that identifies any blockers requiring contract or workflow changes.",232,255,487,226,251,0.003976
2025-12-13T17:54:20,105,resp_0163d7df6b3550d700693d29bc46708190b448796dea4a14ac,gpt-5.2,"[Origin Task]:  
A regional hospital system and its employer-sponsored health plan want to launch a 12‑month digital hypertension management program using remote blood-pressure cuffs, a smartphone app, and pharmacist-led medication titration for 8,000 covered employees across three U.S. states. They must decide whether to operate the program in-house or contract with a telehealth vendor while ensuring compliance with HIPAA and state-specific telemedicine and pharmacy practice rules (including prescribing authority, supervision requirements, and cross-state care) and minimizing clinical risk to participants with comorbid diabetes or chronic kidney disease. Using provided baseline claims data (current annual stroke/MI incidence, average inpatient and outpatient costs, medication adherence rates) and program assumptions (expected BP reduction, enrollment and dropout rates, device costs, staffing costs, and adverse-event probabilities), estimate the break-even point and expected net savings under conservative and optimistic scenarios, and quantify how results change if only 40% of eligible members enroll. Based on the clinical safety constraints, regulatory feasibility, and quantitative ROI findings, deliver a recommendation on the operating model (in-house vs vendor), the states where rollout should start, and the key contract/policy requirements that must be in place before launch.",232,249,481,226,245,0.003892
2025-12-13T17:54:28,106,resp_0050d122bbc88e7d00693d29c457a8819b83d478188c599f64,gpt-5.2,"[Origin Task]:
A mid-sized U.S. county health department is considering launching a 12‑month mobile hypertension program that sends nurses and community health workers to workplaces to provide blood-pressure screening, medication counseling, and same-day referrals, funded partly by an employer coalition that wants de-identified outcomes dashboards. The department must decide whether the program can legally operate under HIPAA/public-health authority while sharing aggregated results with employers, and whether nurse scope-of-practice and informed-consent requirements in the state allow medication counseling and referral workflows without a physician on-site. Using local prevalence data, projected participation rates, expected BP reduction effects from published clinical studies, and program costs (staffing, van lease, equipment, and follow-up), estimate the number of cardiovascular events avoided and compute cost per quality-adjusted life year (QALY) versus the county’s willingness-to-pay threshold, including sensitivity analysis for uptake and adherence. Also assess medical risk controls (e.g., handling hypertensive urgency, contraindication screening, documentation standards) and potential liability exposure for the county and employers. Produce a recommendation memo stating whether to proceed, modify, or cancel the program and specify the minimum legal, clinical, and quantitative criteria that must be met before launch.",232,251,483,226,247,0.00392
2025-12-13T17:54:34,107,resp_092db25bce20d92600693d29caee68819a9a6bfb7a8c3bee3e,gpt-5.2,"[Origin Task]:
A county public health department plans to launch a mobile clinic program that offers same-day COVID/flu vaccination and basic diabetes screening at shelters and public libraries, using an app to schedule visits and store test results and consent forms. After a pilot month, two adverse events occurred (one fainting episode after vaccination requiring EMS transport and one dangerously high glucose reading that was not followed up for 48 hours), and a local advocacy group has filed a complaint alleging improper medical supervision and unlawful handling of personal health data. Using applicable healthcare regulations and privacy laws (e.g., scope-of-practice for vaccinators, consent/refusal documentation requirements, HIPAA/State privacy rules for mobile units and third-party app vendors), clinical safety standards for vaccination and screening, and quantitative analysis of incident rates and staffing/response-time capacity, determine whether the program can legally and clinically continue as designed, what minimum staffing/protocol changes are required, and whether the app workflow must be changed or replaced. Calculate the expected number of adverse events and missed follow-ups per 10,000 encounters under the proposed revised staffing model using the pilot data and projected volume, and estimate the budget impact of compliance-driven changes versus program benefits measured in prevented ER visits. Provide a go/no-go recommendation to the health commissioner, including the legally defensible operating model and the quantitative thresholds that must be met before relaunch.",232,280,512,226,276,0.004326
2025-12-13T17:54:41,108,resp_06319490b6ca312a00693d29d1e81c819889ab232d2c4dfbf9,gpt-5.2,"[Origin Task]:
A US-based regional hospital system is considering launching a telehealth weight-management program that prescribes GLP-1 medications to adults in three states (California, Texas, and New York) and wants to market “average 12% weight loss in 6 months” based on pilot outcomes, while also offering an employer-sponsored pricing bundle that includes quarterly labs and remote monitoring devices. The compliance team is concerned about state-specific telemedicine prescribing rules, controlled-substance and online advertising restrictions, and whether any program features could trigger HIPAA, state privacy laws, or anti-kickback/self-referral concerns when employers subsidize copays and devices. The clinical leadership needs to set medical eligibility/exclusion criteria (e.g., pregnancy, pancreatitis history, renal impairment), monitoring frequency, and escalation pathways for adverse events, while finance needs a quantitative model estimating expected adverse event rates, average per-member-per-month cost, and break-even enrollment under different adherence and discontinuation scenarios using the pilot data and published incidence ranges. As the external consultant, deliver a single go/no-go recommendation and a compliant program design summary that integrates the legal/regulatory constraints, clinical safety protocol, and the quantitative business case for the first 12 months of rollout.",232,253,485,226,249,0.003948
2025-12-13T17:54:47,109,resp_070c00de40d7a52500693d29d80da08197ad695d4f1ad16cb2,gpt-5.2,"[Origin Task]:
A U.S.-based home health agency that serves Medicare beneficiaries wants to roll out a remote patient monitoring (RPM) program for 600 heart-failure and COPD patients using Bluetooth devices and a nurse call center, but leadership is concerned about HIPAA privacy/security requirements, state telehealth and nursing scope-of-practice rules in three operating states (CA, TX, FL), and clinical safety risks from false alerts and delayed escalations. Using the vendor’s published device performance (sensitivity 92%, specificity 88% for decompensation alerts) and the agency’s historical data (monthly decompensation prevalence 8%, average cost per hospitalization $18,500, and staff cost $42 per nurse call), estimate expected monthly alert volumes, true/false positives, downstream workload, and net cost impact under two escalation policies (call every alert vs. call only alerts plus symptom questionnaire) while ensuring the workflow remains legally compliant and clinically appropriate for nursing triage. The agency also plans to store RPM data in a cloud system with subcontractors, raising questions about required Business Associate Agreements, minimum necessary access, breach notification timelines, and whether any state rules impose stricter consent or data-retention obligations. Provide a recommendation on whether to proceed and, if so, which escalation policy and compliance controls to adopt, including a quantitative justification and a summary of the key legal/clinical constraints that drive the decision.",232,287,519,226,283,0.004424
2025-12-13T17:54:55,110,resp_079523929ad4375f00693d29df714c8195ac06fef597199de7,gpt-5.2,"[Origin Task]:  
A U.S.-based regional hospital system is partnering with a large employer to launch an onsite clinic and a mobile app that screens employees for hypertension and type 2 diabetes risk, offers telehealth follow-ups, and provides financial incentives for meeting biometric targets. After a pilot, leadership must decide whether to scale the program to 40,000 employees across three states, but they need to reconcile clinical safety (e.g., false positives/negatives, appropriate referral thresholds, medication management boundaries), legal/regulatory constraints (HIPAA privacy, ADA wellness program nondiscrimination and incentive limits, state telemedicine and licensure rules, and any employer access restrictions to health data), and the program’s financial impact. Using the pilot data (screening rates, prevalence, referral completion, adverse events, and cost/utilization changes) plus projected participation under different incentive levels, estimate the expected net cost or savings over 24 months and quantify the risk of regulatory noncompliance under at least two rollout designs. Deliver a recommendation on whether to scale, which incentive and data-sharing model to adopt, and what clinical protocols and consent language must be included to keep the program medically safe and legally defensible.",232,245,477,226,241,0.003836
2025-12-13T17:55:02,111,resp_066a34a06f9f48a800693d29e683f08194a356c02c25b51ee9,gpt-5.2,"[Origin Task]:
A mid-sized U.S. hospital system is considering launching a pharmacist-led “test-and-treat” program in its retail clinics to prescribe Paxlovid for eligible adults with suspected COVID-19 based on rapid antigen tests and a short intake questionnaire, with follow-up telehealth monitoring. Leadership needs to decide whether the program is legally permissible across two states (one with stricter collaborative practice rules), clinically safe given common contraindications (renal impairment, liver disease, pregnancy considerations, and major drug–drug interactions), and financially viable under expected payer reimbursement and staffing constraints. Using projected weekly patient volume, estimated eligibility rates, adverse event probabilities, and avoided hospitalization rates, quantify net clinical impact and net cost (including liability/insurance cost changes) under best/base/worst-case assumptions, and assess compliance requirements under state scope-of-practice laws, federal EUA/labeling rules, HIPAA, and documentation standards. Provide a recommendation on whether to proceed, modify, or cancel the rollout, and specify the minimum policy safeguards and monitoring metrics needed to implement it responsibly.",232,218,450,226,214,0.003458
2025-12-13T17:55:08,112,resp_056c23b03683237600693d29ec89188193a1d8fcea2bd65864,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is considering launching an AI-assisted “rapid stroke triage” program that uses ambulance-collected vitals and a smartphone video exam to recommend bypassing smaller facilities and routing suspected stroke patients directly to a comprehensive stroke center. Using the system’s last 18 months of EMS and ED data (volumes by ZIP code, door-to-needle times, hemorrhagic vs ischemic rates, false-positive stroke activations, transfer delays, and 30/90-day outcomes), quantify the expected net clinical impact (e.g., incremental QALYs or deaths/disability avoided) and the financial impact under Medicare/Medicaid and commercial reimbursement, including penalties or bonuses tied to quality metrics. Determine the legal/regulatory requirements and risks—HIPAA/42 CFR Part 2 data sharing with EMS, state telemedicine and scope-of-practice constraints, FDA/software-as-a-medical-device considerations, EMTALA obligations when diverting ambulances, and malpractice exposure if the algorithm is wrong—and specify what governance and consent/notice model the hospital should adopt. Based on those analyses and reasonable operational assumptions (staffing, training, device costs, on-call neurologist coverage, and ambulance turnaround time), recommend whether to deploy system-wide, pilot in selected counties, or defer, and produce a decision memo that the CEO can take to the board.",232,281,513,226,277,0.00434
2025-12-13T17:55:16,113,resp_0a916825e1bb8b9300693d29f4606481949cb758db35a4c63c,gpt-5.2,"[Origin Task]:
A U.S. public school district is considering launching an AI-assisted mental health screening program for middle and high school students that uses short questionnaires plus optional passive data from a school-issued wellness app, and it wants to decide whether to proceed and under what conditions. Using applicable federal and state legal requirements (e.g., FERPA, HIPAA boundaries, COPPA/parental consent rules for minors, state mental health consent and mandatory reporting duties, and disability nondiscrimination obligations), clinical standards for adolescent mental health screening and referral, and quantitative analysis of expected false positives/negatives (given vendor-supplied sensitivity/specificity, district prevalence estimates, and counseling staff capacity), determine whether the program can be deployed compliantly and ethically without overwhelming services. The district has 18,000 students, 12 counselors, a maximum of 900 additional counseling sessions per semester capacity, and the vendor claims 82% sensitivity and 90% specificity; the district estimates a 6% prevalence of moderate-to-severe depression/anxiety requiring follow-up, and each flagged student typically needs 3 sessions plus potential external referral. Provide a go/no-go recommendation and, if “go,” specify the minimum consent/notice structure, data retention/sharing limits, triage thresholds or sampling strategy needed to keep expected workload within capacity, and the referral/mandatory-reporting workflow the district should adopt.",232,284,516,226,280,0.004382
2025-12-13T17:55:23,114,resp_07580aa1ca45cce900693d29fb7c308196aee180889df0c9bd,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is considering launching an employer-sponsored “weight management + GLP-1 medication” program for its 8,000 employees (including dependents) and wants to offer telehealth prescribing, bundled lab monitoring, and optional nutrition coaching through a third-party vendor. Leadership needs an analysis that combines clinical appropriateness and safety screening (contraindications, monitoring cadence, adverse-event escalation), legal/regulatory constraints (HIPAA privacy, state telemedicine prescribing rules for controlled/non-controlled substances, ERISA/ACA nondiscrimination and wellness-program incentives, and ADA implications), and a quantitative budget-impact model estimating 12‑month net cost/savings using projected enrollment, medication adherence drop-off, expected changes in diabetes and cardiovascular claims, and productivity/absenteeism assumptions. The organization is also negotiating with its pharmacy benefit manager and must compare two benefit designs: covering GLP‑1s with prior authorization vs. offering a capped stipend with no coverage, while maintaining regulatory compliance and minimizing inequity for lower-income staff. Using the provided claims summary, proposed vendor fees, and a draft clinical protocol, produce a recommendation on whether to proceed and which benefit design to adopt, including the key policy language and the financial threshold (break-even point) that would justify implementation.",232,265,497,226,261,0.004116
2025-12-13T17:55:30,115,resp_01eeab9780026cd700693d2a02a0a88195a150f14c8efcbfed,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system wants to deploy an AI-driven sepsis early-warning tool that continuously ingests EHR data and wearable heart-rate/temperature data for all adult inpatients, and it plans to begin with an “opt-out” consent model to maximize uptake while sharing de-identified performance logs with a university partner. After a pilot, leadership must decide whether to scale to 10 hospitals, but clinicians report alarm fatigue and the compliance team is unsure whether the wearable data and model outputs trigger additional HIPAA obligations, state privacy requirements, or FDA clinical decision support/device regulation, especially if alerts are routed to nurses and automatically open order sets. Using the pilot metrics (12,000 admissions; sepsis prevalence 3.0%; sensitivity 0.82; specificity 0.90; average alert review time 6 minutes; average RN fully loaded cost $58/hour; estimated 15% relative reduction in sepsis mortality if treated within 1 hour; baseline sepsis mortality 18%; potential added adverse antibiotic events 0.4% of alerted non-sepsis patients) and the system’s planned staffing, determine whether scaling is ethically and operationally justified and legally permissible under a proposed governance/consent approach. Provide a go/no-go recommendation with quantified expected net clinical benefit and labor cost impact, and specify the minimum compliance and clinical safety constraints the hospital must implement before rollout.",232,288,520,226,284,0.004438
2025-12-13T17:55:39,116,resp_06c243ffc959930900693d2a0b4720819a8c63541749e55005,gpt-5.2,"[Origin Task]:
A mid-sized U.S. manufacturing company is considering launching an optional on-site clinic that would provide seasonal influenza and COVID-19 vaccinations, blood-pressure/diabetes screening, and limited treatment for minor injuries, staffed by a contracted nurse practitioner and using a third-party telehealth physician group for prescribing. Leadership needs to determine whether the clinic model can be structured to comply with HIPAA/OSHA and applicable state scope-of-practice and telemedicine rules while minimizing employment-law risk (e.g., ADA/FMLA implications if screening results affect job duties), and to draft a compliant employee consent and data-sharing policy between the employer, clinic vendor, and health plan. At the same time, finance wants a quantitative business case estimating expected annual net cost/savings using assumptions about participation rates, vaccine effectiveness on absenteeism, baseline injury/illness rates, workers’ compensation claim reductions, vendor fees, and potential liability/penalty exposure under different compliance scenarios. Provide a recommendation on whether to proceed and which clinic structure (services offered, staffing model, data flows, and eligibility rules) should be adopted, supported by the legal/healthcare compliance rationale and a sensitivity analysis showing the break-even point and worst-case downside risk.",232,251,483,226,247,0.00392
2025-12-13T17:55:45,117,resp_09f503381ef530d300693d2a11d1ac81939dbb6728999bb486,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering launching a voluntary after-school weight-management and mental-health screening program for students ages 12–17, using a vendor’s app that collects symptom surveys, heart-rate data from wearables, and occasional telehealth visits with nurse practitioners. The district must decide whether to deploy the program districtwide next semester and how to structure parental consent/assent, data sharing with schools and clinicians, and emergency protocols for self-harm risk, while complying with HIPAA/FERPA, state minor-consent rules, and mandatory reporting obligations. Using published pediatric screening and intervention data, estimate expected benefits and harms (e.g., reduced obesity prevalence, detection of depression/anxiety, false positives leading to unnecessary referrals) and quantify budget impact, staffing needs, and cost-effectiveness under at least two uptake-rate scenarios and two referral-rate assumptions. Also assess the legal exposure and compliance requirements for storing and transmitting health data, and propose a defensible policy on data retention, access controls, and when/how school staff may be notified of elevated risk. Deliver a recommendation to the school board on whether to proceed, under what conditions (contract clauses, clinical oversight model, consent language), and the projected 12-month financial and health outcomes.",232,259,491,226,255,0.004032
2025-12-13T17:55:52,118,resp_0cacabcab0bdfb9d00693d2a181bc8819ba0a7cca490e9dfa1,gpt-5.2,"[Origin Task]:
A 600-employee U.S. manufacturing company is considering launching an on-site clinic and wellness program to reduce health-related absenteeism, but leadership is concerned about legal exposure and clinical safety after a recent cluster of heat-related illnesses and one opioid-related workplace incident. Using last year’s HR and claims data (e.g., 9,200 sick-leave hours, average fully loaded hourly cost $48, ER/urgent-care spend $410,000, and an estimated 18% of absences tied to musculoskeletal pain), evaluate whether the proposed program (staffed by one NP, one medical assistant, and a part-time physical therapist; annual operating cost $620,000; projected reductions: 20% fewer ER/urgent-care visits and 12% fewer sick-leave hours) is likely to be cost-effective over 24 months under conservative assumptions and sensitivity analysis. In your assessment, account for healthcare compliance requirements and risk constraints (HIPAA privacy, ADA accommodations, OSHA heat illness prevention, controlled-substance prescribing limits, and state scope-of-practice rules for NPs/PTs) and clinical protocols needed to avoid harm (triage criteria, referral thresholds, opioid stewardship, and documentation standards). The company also wants to offer incentives (up to $600/year per employee) for participation and biometric screening, but must ensure the program structure does not create unlawful coercion or discrimination and that any data-sharing with management is legally compliant. Provide a recommendation on whether to proceed, modify, or abandon the program and specify the minimum compliant operating model and quantitative ROI thresholds the board should require before approval.",232,329,561,226,325,0.005012
2025-12-13T17:56:00,119,resp_0ee8b767d370444000693d2a20c6a88190bf6f20b2bea3a751,gpt-5.2,"[Origin Task]:  
A U.S. county public school district plans to deploy an AI-driven mental-health screening program for students ages 12–18 that uses periodic questionnaires plus optional wearable heart-rate data to flag suicide-risk and automatically schedule telehealth visits through a contracted clinic. The district’s board needs to decide whether and how to launch the program while complying with FERPA, HIPAA (as applicable to the clinic and data flows), and relevant state minor-consent and mandatory reporting laws, including what parental consent/opt-out model is legally defensible and what disclosures are required. Using the vendor’s pilot statistics (sensitivity 82%, specificity 90%, base-rate of high-risk students estimated at 2.5%) and the district’s population (18,000 students), quantify expected true/false positives and the downstream clinical capacity required (e.g., clinician-hours per week if each flagged student receives a 45-minute initial assessment and 15-minute follow-up for confirmed high-risk cases). Also assess likely medical and operational risks (e.g., over-referral burden, under-detection, handling of acute-risk alerts during off-hours) and translate those into a policy decision on alert thresholds, escalation protocols, and staffing/contract terms. Prepare a board-ready recommendation on whether to proceed this semester, and if so, the minimum viable compliance and clinical workflow design that balances student safety, legal exposure, and resource constraints.",232,288,520,226,284,0.004438
2025-12-13T17:56:08,120,resp_0143e188f48c775e00693d2a2897f0819998ea62ca4912e3df,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering installing AI-enabled fever-scan kiosks at all building entrances to reduce infectious disease spread, and plans to automatically notify parents, the school nurse, and the local health department when a student’s temperature exceeds a threshold. The superintendent needs an analysis that combines medical evidence (appropriate fever thresholds, false-positive/false-negative implications, and clinical follow-up protocols), legal/regulatory compliance (FERPA, HIPAA applicability for school health records, state health-reporting laws, consent requirements for minors, data retention, and vendor contracting/privacy terms), and quantitative modeling (projecting expected detections per day, staffing and referral workload, costs per true case prevented, and sensitivity analyses across prevalence scenarios). The district must also address common-sense operational constraints like morning bottlenecks, equity/access concerns for students arriving late or via buses, and contingency plans for device failures. Prepare a recommendation on whether to implement the kiosks districtwide this semester, including a defensible threshold and notification policy, minimal necessary data fields and retention period, and a budget-impact estimate with key risks and mitigations.",232,232,464,226,228,0.003654
2025-12-13T17:56:13,121,resp_0eb1beaae6ca593e00693d2a2d8794819baaac0fc21120d01a,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering launching a voluntary after-school program in which trained staff administer OTC naloxone and epinephrine auto-injectors during emergencies, store these medications on-site, and collect minimal health information from participating students to improve response times. The district’s counsel is worried about compliance with federal and state laws (e.g., HIPAA/FERPA boundaries, state “stock epinephrine/naloxone” statutes, consent and Good Samaritan protections, and liability exposure), while the medical director wants protocols that are clinically appropriate for adolescents and align with standard-of-care training, storage, and documentation. The superintendent also needs a quantitative estimate of expected medical benefit versus cost: using local overdose/anaphylaxis incidence estimates, response-time assumptions, medication shelf-life/wastage, staffing/training hours, and probability-of-survival curves, compare two options—(A) stock medications at all 12 campuses with annual refresher training, or (B) stock only at 4 hub campuses with faster EMS dispatch coordination—over a 3-year budget window. Produce a recommendation for the board that selects an option (or a modified hybrid), specifies the legally compliant consent/data-handling approach, outlines the clinical protocol at a high level, and includes a numeric cost-benefit/risk summary suitable for a public meeting.",232,278,510,226,274,0.004298
2025-12-13T17:56:19,122,resp_0da419656234720500693d2a33f098819a8116b9fb2521e0eb,gpt-5.2,"[Origin Task]:  
A U.S.-based grocery chain with 180 stores is considering adding automated blood-pressure kiosks and on-site pharmacists to deliver brief hypertension screening and referrals, and wants to market the service through its loyalty app. Using projected kiosk utilization (average 22 screenings/store/day), observed prevalence of stage-2 hypertension in similar settings (9.5%), expected referral follow-through (42%), and an estimated reduction in ER visits among adherent patients (0.018 ER visits avoided/person/month), quantify the annual health impact and the break-even price per screening given fixed startup costs of $8.2M, annual operating costs of $5.6M, and an assumed value of $1,750 per ER visit avoided (include sensitivity for ±20% utilization). Determine what federal and state legal constraints apply to this model (e.g., HIPAA/FTC privacy for app-based marketing, scope-of-practice and collaborative practice rules, and whether the kiosks or decision-support features trigger FDA device or clinical laboratory regulation), and what consent/disclosure language is required to reduce liability for missed diagnoses. Also assess key medical safety considerations (contraindications for immediate referral, handling hypertensive urgency readings, and protocols for repeat measurements) and propose a compliant, clinically appropriate operating policy that aligns with the quantified financial and public-health outcomes. Based on these analyses, recommend whether the chain should launch chainwide, pilot in select states, or not proceed, and specify the minimum conditions that must be met before launch.",232,308,540,226,304,0.004718
2025-12-13T17:56:26,123,resp_0b17c6d75aef818a00693d2a3a7098819988e09e3ea00bf359,gpt-5.2,"[Origin Task]:
A regional public hospital system is considering launching an AI-assisted stroke triage program in its emergency departments that analyzes patient symptoms and imaging to recommend thrombolytic treatment and automatically triggers a tele-neurology consult, but leadership is concerned about patient safety, clinician liability, and privacy compliance. Using current U.S. healthcare regulations (including HIPAA and applicable FDA/medical-device oversight for clinical decision support), assess what legal/operational safeguards and patient-consent or notice requirements are needed for deployment, and identify any restrictions on using de-identified vs. identifiable data for model monitoring and improvement. Clinically, estimate how the program would change outcomes by modeling expected differences in door-to-needle time and resulting changes in rates of functional independence and symptomatic intracranial hemorrhage, using provided baseline volumes (e.g., 2,400 suspected strokes/year across 6 EDs), current treatment rates, and published risk/benefit parameters. Quantitatively compare two rollout options—(A) deploy system-wide immediately vs. (B) a 12‑month pilot in 2 EDs—by calculating expected net clinical benefit (e.g., QALYs gained or adverse events avoided), staffing costs, malpractice risk exposure proxies, and total cost of ownership under plausible sensitivity ranges. Deliver a recommendation on whether to proceed, which rollout option to choose, and the minimum compliance, governance, and clinical protocol changes required before go-live.",232,293,525,226,289,0.004508
2025-12-13T17:56:32,124,resp_06de401769e7064c00693d2a40ad1481948540185b0e03e686,gpt-5.2,"[Origin Task]:  
A U.S.-based regional hospital system plans to deploy an AI-driven sepsis early-warning tool that continuously analyzes EHR vitals and lab values and automatically triggers a rapid-response protocol, but leadership is concerned about patient safety, clinician workload, and legal exposure. Using last year’s de-identified data (60,000 adult admissions; sepsis prevalence 4.5%), the vendor reports sensitivity 0.82 and specificity 0.90 at the proposed threshold, while the hospital estimates that each false alert costs 20 minutes of nurse time and $45 in disposables, and each missed sepsis case increases expected inpatient cost by $18,000 and mortality risk by 3.0 percentage points. The hospital must also comply with HIPAA (including minimum necessary access and BAA requirements), CMS Conditions of Participation for patient safety and quality, and relevant state informed-consent and medical device/clinical decision support rules for notifying patients about AI involvement and ensuring clinician oversight. Prepare a recommendation to the board on whether to deploy the tool at the proposed threshold, including the expected annual number of true/false alerts, net financial impact, and a compliance/safety policy position (e.g., documentation, clinician override, audit logging, and patient notice) that minimizes regulatory and malpractice risk while maintaining clinical effectiveness.",232,270,502,226,266,0.004186
2025-12-13T17:56:39,125,resp_0a2dd6bd84ec844500693d2a472f5881938d51c7de40cc8833,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering installing continuous indoor air-quality sensors and offering optional annual spirometry screening for staff and high-risk students to reduce asthma-related absences, but the vendor will store sensor data and test results in a cloud dashboard accessible to administrators and the district’s contracted occupational health clinic. Using common-sense operational constraints (limited nurse staffing, class-time disruption, and parent communications), applicable legal/regulatory requirements (FERPA for student records, HIPAA where the clinic is involved, state minor-consent and privacy rules, and data-retention/breach-notification obligations), and healthcare considerations (clinical appropriateness of screening, referral thresholds, and risks of false positives/negatives), evaluate whether the proposed program can be implemented without creating undue liability or inequitable access. Then perform a quantitative analysis projecting 3-year costs and benefits: device and service fees, clinic labor, expected reduction in asthma-related absences and substitute-teacher costs, and sensitivity to varying participation rates and sensor accuracy. Based on this integrated assessment, deliver a recommendation on whether to proceed, what minimum policy/contract changes are required (consent, access controls, retention, incident response), and a go/no-go decision with budget ranges and key risk mitigations.",232,259,491,226,255,0.004032
2025-12-13T17:56:45,126,resp_018e44b5eae5140c00693d2a4d91f481948fe0ffdcc5eaee44,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system plans to launch an employer-facing “hypertension reduction” program that combines remote blood-pressure cuffs, a medication-adherence app, and pharmacist-led telehealth visits, and it wants to market outcomes-based pricing to self-insured employers while sharing de-identified analytics with a third-party data vendor. Using the hospital’s last 12 months of claims and clinical data (provided), determine whether the proposed program is likely to be clinically appropriate and cost-saving over a 18‑month contract term by modeling expected reductions in stroke/MI events, medication adherence changes, and downstream utilization, including confidence intervals and sensitivity analyses. At the same time, assess the regulatory feasibility of the data flows and contracting model under HIPAA (including de-identification standards and BAAs), federal Anti‑Kickback Statute and Stark Law risks related to employer referrals and outcomes-based payments, and any state telehealth/pharmacy practice constraints in the three states where patients reside. Based on your combined clinical, quantitative, and legal assessment, recommend whether the hospital should proceed as designed, modify specific elements (and which), or halt the launch, and provide a defensible written rationale suitable for executive approval.",232,248,480,226,244,0.003878
2025-12-13T17:56:51,127,resp_02c40c72a46fedbc00693d2a534f5c8198819b43858f7a8332,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering installing UV-C air disinfection units and upgrading HVAC filtration across 40 schools to reduce respiratory illness transmission, but it must decide whether the program is justified given health risks, legal constraints, and limited funds. Using current medical evidence on UV-C effectiveness and potential adverse effects (e.g., ozone generation and eye/skin exposure), assess the expected reduction in student/staff sick days and asthma exacerbations, and quantify the projected annual cost savings and QALY impact under conservative and optimistic assumptions. Evaluate the district’s regulatory and liability obligations (e.g., OSHA indoor air and worker safety duties, state public health guidance, procurement and building-code compliance, and parental consent/notification requirements if exposure risks exist) and identify any conditions that would make deployment legally nonviable. Based on a quantitative cost–benefit analysis (including uncertainty ranges and sensitivity to infection rates and device performance) and a legally compliant risk-mitigation plan, deliver a recommendation on whether to proceed, which schools to prioritize first, and the maximum per-school budget that still meets a specified threshold (e.g., <$50,000 per QALY gained) while keeping legal exposure acceptably low.",232,251,483,226,247,0.00392
2025-12-13T17:56:56,128,resp_03a83b7f207705fd00693d2a58a23081999db156a705e1cd12,gpt-5.2,"[Origin Task]:
A 900-employee U.S. manufacturing company with plants in California and Texas is considering rolling out an opt-in program that uses quarterly finger-stick HbA1c testing and wearable activity data to identify employees at high risk for type 2 diabetes and offer premium discounts plus on-site coaching, but leadership is concerned about medical appropriateness, privacy, and discrimination risk. Using current clinical guidelines and occupational-health best practices, determine what screening thresholds, referral pathways, and contraindications should apply, and assess whether the program design could inadvertently pressure participation or create adverse employment actions for workers with disabilities or chronic conditions. Evaluate compliance requirements under HIPAA (including when the company becomes a covered entity or business associate), the ADA and GINA (limits on medical inquiries and genetic information), and applicable state privacy and workplace laws for CA and TX, including what notices, consents, data-retention limits, and vendor contract terms are needed. Quantitatively model the expected annual financial impact: estimate program costs (testing, devices, coaching, administration), expected participation rates, projected reduction in diabetes incidence and claims over 3 years, and sensitivity to false positives/negatives and employee turnover. Deliver a recommendation on whether to launch, modify, or cancel the program and specify the final policy language elements required for a compliant, medically sound, and cost-justified rollout.",232,278,510,226,274,0.004298
2025-12-13T17:57:02,129,resp_0a1e4857c5472cd700693d2a5eae688194a04d56d0b45d06a4,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is deciding whether to install CO₂ monitors and upgrade HVAC in 42 classrooms to reduce respiratory infection spread while complying with OSHA guidance, state indoor air quality rules, and FERPA/HIPAA constraints for any health-related data collected from students and staff. The superintendent has a $1.8M capital budget and must choose between (a) portable HEPA units plus CO₂ monitors, (b) ducted HVAC upgrades to meet ASHRAE ventilation targets, or (c) a hybrid approach, and needs to estimate impacts on asthma exacerbations and absenteeism given local pediatric asthma prevalence, baseline attendance, and published risk-reduction effect sizes. Using provided vendor quotes, energy-cost projections, and staffing constraints, determine which option minimizes total expected 5-year cost (capital + operating + expected medical/absenteeism costs) while meeting applicable legal/regulatory requirements and reasonable medical safety standards. Produce a recommendation memo that includes the quantitative comparison, key compliance risks and mitigations, and the final procurement choice to present for board approval next month.",232,225,457,226,221,0.003556
2025-12-13T17:57:08,130,resp_06912a21823eee2100693d2a64fc70819487b81dfc0eb71e35,gpt-5.2,"[Origin Task]:
A county public school district is considering deploying a cloud-based AI system to screen students (ages 12–18) for depression risk using brief questionnaires and optional smartwatch heart-rate/sleep data, with alerts sent to school counselors and, for high-risk cases, to parents and an on-call telehealth clinician. After a recent incident, the board must decide whether the program can be launched next semester while complying with applicable student privacy and health-data rules (e.g., FERPA, HIPAA/telehealth obligations, mandatory reporting, parental consent/opt-out, data retention and breach-notification requirements) and ensuring the screening process is clinically appropriate and minimizes harm (false positives/negatives, crisis escalation, equity concerns). The vendor offers two configurations: Model A (higher sensitivity, lower specificity) and Model B (lower sensitivity, higher specificity); using the district’s enrollment counts, estimated baseline prevalence of moderate-to-severe depression, and the counselor/telehealth capacity limits and per-student costs provided in the proposal, the district needs a quantitative comparison of expected true/false alerts, staffing hours, and total annual program cost under each model, including the impact of different consent participation rates. Prepare a go/no-go recommendation choosing A, B, or a modified rollout (e.g., pilot, grade-limited, opt-in only) that integrates the legal compliance plan, clinical safety protocol, and the quantitative capacity/cost analysis, and specifies the minimum contractual clauses and operational policies the district must require before signing.",232,309,541,226,305,0.004732
2025-12-13T17:57:16,131,resp_04ebed912815a55000693d2a6ca2cc819aa4f9cac73d802a87,gpt-5.2,"[Origin Task]:
A mid-sized U.S. public school district is considering launching a voluntary “asthma-and-allergy safety” program that would (1) collect students’ peak-flow readings and symptom reports via a mobile app, (2) allow the school nurse to adjust rescue-inhaler access plans, and (3) share de-identified aggregate data with a university partner for research while billing certain nurse telehealth check-ins to Medicaid where eligible. The district must decide whether to approve the program before the next school year, given constraints around parental consent, FERPA/HIPAA boundaries, state minor-consent and school-medication administration rules, and whether the data-sharing and billing practices create legal exposure. Using medically appropriate asthma monitoring thresholds and school-based care standards, quantify expected health impact and operational risk by estimating reductions in ER visits and missed school days versus program costs, staffing time, and potential privacy/breach liability (include a sensitivity analysis for different participation rates and breach probabilities). Provide a recommendation on whether to proceed and, if so, specify the required compliance posture (consent language, data minimization, retention, de-identification standard, and billing documentation) and the maximum per-student annual budget that keeps the program cost-effective under your assumptions.",232,257,489,226,253,0.004004
2025-12-13T17:57:22,132,resp_0ecdbdc66ce8abfb00693d2a725c2081989f5ff41e1c89d725,gpt-5.2,"[Origin Task]:
A mid-sized U.S. employer (1,200 employees across California and Texas) is deciding whether to replace its current health plan with a new plan design that adds mandatory annual biometric screenings and a $600 premium surcharge for employees who refuse or fail to meet certain health targets (BMI, blood pressure, A1C), while also offering a telehealth chronic-care program for diabetes and hypertension. Leadership needs an analysis that balances medical appropriateness and risk (false positives, follow-up care burden, clinical contraindications, and equitable accommodations) with legal/regulatory compliance (ADA/GINA wellness program rules, HIPAA nondiscrimination/privacy, ERISA fiduciary duties, and any California-specific privacy/employment constraints) and a quantitative cost/benefit projection over three years. Use the provided baseline data: current annual employer spend is $11.8M; diabetes prevalence 9% and hypertension 22%; expected participation in telehealth is 35% of eligible employees; telehealth reduces related claims by an estimated 12% among participants but increases primary-care visits by 0.4 visits/person/year; screening costs $85 per employee screened; expected refusal rate 18% in year 1 declining to 12% by year 3; average annual premium is $7,200 with employer paying 75%; and estimated turnover cost is $9,000 per departing employee, with a projected additional 0.6% annual attrition if surcharges are perceived as punitive. Prepare a recommendation on whether to adopt, modify, or reject the new plan design, including the maximum legally defensible surcharge/incentive structure and any required medical exceptions/accommodations, and quantify the net financial impact and key compliance risks under the stated assumptions.",232,356,588,226,352,0.00539
2025-12-13T17:57:29,133,resp_07a72e880a7b6e5a00693d2a795da8819ab3341747acbef924,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is considering launching a pharmacist-led hypertension program that uses an FDA-cleared blood-pressure cuff paired with a mobile app to collect daily readings from 4,000 adult patients, triage alerts to a centralized nursing team, and share data with primary-care physicians and a third-party analytics vendor. The leadership needs to confirm whether the proposed data flows and consent language comply with HIPAA and applicable state privacy/telehealth rules (including whether the vendor relationship requires specific contractual terms), while ensuring the clinical protocol meets standard-of-care expectations for medication titration, escalation thresholds, and handling hypertensive urgencies. Finance also requires a quantitative projection comparing program costs (devices, staffing, vendor fees) against expected reductions in emergency visits and strokes, including a sensitivity analysis using published baseline event rates and assumed adherence levels, plus an estimate of potential liability exposure if alerts are delayed. Based on these constraints, produce a go/no-go recommendation and specify the legally compliant operational model, the clinically safe monitoring/escalation policy, and the numeric budget-impact case the board should rely on to decide within 30 days.",232,232,464,226,228,0.003654
2025-12-13T17:57:34,134,resp_06ab6a4130563b0c00693d2a7eb824819b823c65ff55b032e1,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying an AI-enabled thermal camera and symptom-check kiosk at building entrances to reduce seasonal influenza and COVID-19 spread, and it wants to share aggregated risk dashboards with the county public health department. Using current U.S. legal/regulatory requirements (e.g., HIPAA applicability, FERPA, state biometric/privacy laws, consent rules for minors, data retention and breach notification), clinical evidence on screening effectiveness and false positives/negatives, and quantitative modeling of expected cases prevented versus harms (missed cases, unnecessary exclusions, staffing time, and costs), assess whether the program is lawful and medically defensible. Incorporate a budget constraint of $750,000 for year one, 18 schools, 9,000 students, expected baseline absenteeism of 6% per day in peak season, and an assumed kiosk sensitivity/specificity that must be justified from published ranges. Deliver a recommendation on whether to proceed, modify, or cancel the program, and specify the minimum compliant policy terms (consent, data minimization, retention period, access controls, and reporting granularity) that the district should adopt if it proceeds.",232,242,474,226,238,0.003794
2025-12-13T17:57:39,135,resp_071ef099d83aa23a00693d2a840e808196a945fb86eb370ff1,gpt-5.2,"[Origin Task]:
A regional hospital system is considering launching a pharmacist-led telehealth program to prescribe and mail nirmatrelvir/ritonavir (Paxlovid) to high-risk COVID-19 patients within 5 days of symptom onset, using at-home rapid tests and a brief video visit, across two neighboring states with different rules on pharmacist prescribing, telemedicine, and patient identity verification. The leadership needs an analysis that combines clinical eligibility and contraindication screening (renal/hepatic dosing, drug–drug interactions, pregnancy considerations), applicable federal and state legal/regulatory constraints (scope of practice, telehealth prescribing requirements, HIPAA/42 CFR Part 2 implications, mail-order pharmacy rules, documentation and informed consent), and quantitative modeling of capacity and outcomes (expected eligible volume, turnaround times needed to meet the 5-day window, adverse event risk rates, staffing levels, and budget impact under current payer reimbursement). Using the system’s last winter data—12,000 outpatient COVID-positive cases, 18% age ≥65, 22% with immunocompromise, 40% on ≥1 interacting medication; median symptom-to-test 2.0 days (IQR 1–4); and a target to reduce COVID hospitalizations by 15% while keeping serious adverse drug events under 0.2%—recommend whether to proceed and, if so, define the program’s go/no-go criteria and the minimum staffing and compliance controls required to operate legally and safely in both states.",232,305,537,226,301,0.004676
2025-12-13T17:57:46,136,resp_078ae1f5b1a02fc100693d2a8af3c08199b7e8bdbb3a6a6279,gpt-5.2,"[Origin Task]:
A county public health department plans to launch a 12‑month program that uses an AI-assisted phone triage line to route uninsured residents with symptoms of depression, opioid use disorder, or diabetes complications to either telehealth visits, in‑person clinics, or emergency care, and it must decide whether the program is legally and clinically safe and financially viable. The department will collect call recordings and symptom questionnaires, share limited data with a contracted hospital system and a cloud vendor, and provide follow‑up outreach by community health workers; leadership needs to ensure compliance with HIPAA, 42 CFR Part 2 (substance use treatment records), state consent rules for mental health services, and public-sector procurement/privacy requirements. Using expected call volumes, prevalence estimates, false-negative/false-positive rates of the triage model, local ED diversion costs, clinician staffing constraints, and projected health outcomes, quantify the net budget impact and the medical risk (e.g., expected adverse events from mis-triage) under at least two operational policies (conservative vs. aggressive routing thresholds). Based on the combined legal constraints, clinical safety considerations, and quantitative cost–risk tradeoffs, draft a recommendation on whether to proceed, what minimum safeguards/consent language/data-sharing limits are required, and what routing policy and staffing levels should be adopted.",232,271,503,226,267,0.0042
2025-12-13T17:57:53,137,resp_0eda41c2dc8ee43900693d2a91b5a481908f9115ea97578797,gpt-5.2,"[Origin Task]:
A U.S.-based hospital system is considering deploying an AI-driven clinical triage chatbot for its urgent-care telehealth service that will collect symptoms, medications, pregnancy status, and insurance details, then recommend “home care vs. same-day clinic vs. ER” and automatically schedule appointments across three states (including California). After a pilot month, leadership has data showing the tool reduces nurse triage time by 35% but produced a higher false-negative rate for sepsis red flags (0.6% vs. 0.2% baseline), and they must decide whether to expand systemwide, modify risk thresholds, or pause deployment. Prepare an executive decision memo that (1) evaluates regulatory and liability exposure under HIPAA and state privacy/consumer health data rules (including California requirements), telehealth informed-consent expectations, and whether the chatbot’s functionality could trigger medical-device or clinical decision support compliance concerns; (2) quantifies patient-safety risk and expected harm using the pilot rates, projected monthly volume, and a proposed escalation rule that increases ER referrals by a specified percentage; and (3) recommends a go/no-go path with required clinical safeguards, documentation, and monitoring metrics that balance patient safety, staffing constraints, and financial impact.",232,256,488,226,252,0.00399
2025-12-13T17:58:00,138,resp_0d2b61c4b7eaabb700693d2a98c378819b8055f769e389139a,gpt-5.2,"[Origin Task]:
A U.S.-based school district is deciding whether to install carbon monoxide (CO) detectors and upgrade ventilation in 18 older school buildings after several staff reported headaches and nausea, and two students with asthma were treated at an urgent care visit; the district also worries about legal exposure if another incident occurs. Using recent nurse-visit logs, local hospital/urgent care utilization rates, and indoor air readings (ppm over time) from a one-week pilot in 3 buildings, estimate the expected annual number of CO-related medical visits and the probability of a severe event under status quo versus mitigation, and quantify the total expected cost difference (healthcare costs, missed school/work days, and project capital/maintenance costs) over a 5-year horizon with appropriate discounting. Evaluate the district’s compliance obligations and liability risk under applicable building/fire codes and occupational safety requirements (e.g., state adoption of IFC/NFPA standards, OSHA general duty considerations), including how documentation and response protocols affect exposure. Incorporate medical guidance on CO exposure thresholds, symptom risk in children and people with asthma, and recommended monitoring/response practices to propose an operational policy for alarms and evacuations. Deliver a board-ready recommendation on whether to proceed now, which buildings to prioritize, and what written policy and recordkeeping changes are required to minimize health risk and legal liability while staying within a fixed $2.5M budget.",232,285,517,226,281,0.004396
2025-12-13T17:58:06,139,resp_0523516aa9dcc0ae00693d2a9f07348198a5f1f0795ad7a956,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering deploying a voluntary, opt-in smartphone app for high-school students that uses passive Bluetooth proximity and self-reported symptoms to identify possible meningococcal exposure and trigger recommendations for post-exposure prophylaxis, temporary remote learning, and notification of close contacts. The district’s board needs a policy that satisfies HIPAA/FERPA boundaries, state public-health reporting requirements, parental consent rules for minors, and ADA/anti-discrimination constraints while minimizing legal liability if an outbreak occurs or if students are wrongly flagged. Using the last 3 years of district attendance data and county incidence rates, estimate the expected reduction in secondary cases under three intervention thresholds (e.g., “notify at 10 minutes/2 meters,” “30 minutes/2 meters,” “symptom-only”), quantify false-positive-driven missed school days and staffing costs, and compare these to the expected medical costs avoided and the risk of severe outcomes. Decide which threshold and data-retention/sharing policy the district should adopt and draft the final decision memo to the board recommending whether to launch the program this semester and under what conditions.",232,233,465,226,229,0.003668
2025-12-13T17:58:11,140,resp_0fa87d54455a408800693d2aa403948197b6c812e9af9a20cf,gpt-5.2,"[Origin Task]:
A mid-sized U.S. school district is considering installing a new HVAC and air-filtration system across 12 schools after a spike in asthma-related nurse visits and several staff members requesting ADA accommodations due to respiratory conditions. The superintendent needs an analysis that combines (1) healthcare evidence on expected reductions in asthma exacerbations and absenteeism from improved indoor air quality, (2) applicable legal/regulatory requirements and liability exposure (e.g., OSHA indoor air standards/guidance, ADA reasonable accommodations, state building codes, and public procurement rules), and (3) quantitative modeling of costs and benefits, including capital expenditures, energy-use changes, expected healthcare/absenteeism reductions, and sensitivity analysis under different ventilation targets and filter ratings. Use the district’s last 3 years of attendance, nurse visit logs, local asthma prevalence, and vendor bids to estimate the net present value over 10 years and identify any compliance gaps or legal risks if the district delays action. Deliver a recommendation on whether to proceed now, phase the installation, or adopt interim mitigation measures, and specify the minimum legally defensible and medically effective IAQ performance targets the district should require in the contract.",232,240,472,226,236,0.003766
2025-12-13T17:58:18,141,resp_00dc67b83252be1300693d2aaa71988197a87252218ae2eb35,gpt-5.2,"[Origin Task]:
A mid-sized U.S. hospital system wants to deploy an AI-driven triage chatbot on its public website to advise adults on whether to seek emergency care, urgent care, telehealth, or self-care, and it plans to store conversation logs for 18 months to improve the model while also sending summaries into the EHR when a patient chooses to schedule a visit. After two near-miss incidents involving chest-pain users and one complaint alleging discriminatory advice to non-native English speakers, the compliance officer needs to decide whether to pause the rollout, change data-retention and consent flows, and adjust clinical escalation thresholds. Using applicable legal/regulatory requirements (HIPAA/privacy, FDA/FTC considerations for health claims, and disability/language-access obligations), basic clinical safety constraints for time-sensitive symptoms, and a quantitative analysis of expected harm reduction vs added ED utilization under different sensitivity/specificity thresholds (given assumed symptom prevalence, false-negative costs, and staffing/bed capacity limits), determine a defensible deployment policy. Provide a final recommendation to the hospital CEO on whether to proceed, proceed with modifications, or pause—specifying the minimum consent language, retention period, escalation rules, and monitoring metrics needed to reduce legal exposure and patient-safety risk while staying within operational capacity.",232,260,492,226,256,0.004046
2025-12-13T17:58:25,142,resp_0fefb937f07e2cfd00693d2ab12d6c819a8480eb8d7645ea88,gpt-5.2,"[Origin Task]:
A mid-sized U.S. public school district is considering switching from standard epinephrine auto-injectors to a new generic device for all campuses and also wants to implement a policy allowing trained, non-nurse staff to administer epinephrine during suspected anaphylaxis. Using clinical guidance on anaphylaxis recognition and dosing, applicable federal/state school medication-administration laws and liability/Good Samaritan protections, and a quantitative cost–risk model (including device costs, training time, incident frequency, probability of dosing error, and expected medical outcomes), evaluate whether the switch and policy change reduce overall harm and total annual cost compared with the current approach. Incorporate practical constraints such as storage temperature limits, expiration management, staff turnover, and accessibility during field trips. Deliver a recommendation to the superintendent on whether to adopt the generic device and expand administration authority, including the minimum legally compliant training and documentation requirements and the projected 3-year budget impact.",232,195,427,226,191,0.003136
2025-12-13T17:58:29,143,resp_03ff29ec4970facd00693d2ab60f648197902525adc83fa22e,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system wants to launch an AI-assisted sepsis early-warning program that pulls real-time vitals and lab results from its EHR and sends alerts to bedside clinicians, while also enrolling high-risk patients into an optional remote-monitoring follow-up after discharge. The compliance team is concerned about HIPAA/42 CFR Part 2 data-sharing limits, FDA oversight of clinical decision support software, and state privacy/consent rules, while clinical leadership needs to validate safety (false positives/negatives), set alert thresholds, and define when clinicians must intervene to avoid standard-of-care liability. Using the hospital’s last 12 months of de-identified outcomes (e.g., sepsis incidence, ICU transfers, mortality, length of stay, and alert performance on retrospective runs), the CFO also requires a quantified ROI model that incorporates staffing time, avoidable adverse events, reimbursement impacts, and malpractice risk exposure under different deployment policies. Provide a single go/no-go recommendation for rollout in two pilot hospitals, including the minimum compliance posture, clinical governance requirements, and the quantitative justification for the chosen alert threshold and follow-up enrollment criteria.",232,235,467,226,231,0.003696
2025-12-13T17:58:36,144,resp_093c9f9cf0e2948900693d2abc3e608199bc1537632fab7105,gpt-5.2,"[Origin Task]:
A U.S.-based school district is considering replacing all in-person detention with an after-school “study hall” program that includes optional 20-minute mindfulness sessions led by contracted counselors, and it plans to collect students’ self-reported stress scores plus heart-rate data from wearable devices to evaluate effectiveness. The district must ensure the program and data collection comply with FERPA and applicable state student-privacy laws, determine whether any activities trigger HIPAA obligations for the contractors, and assess medical safety and liability risks for students with anxiety disorders, ADHD, asthma, or arrhythmias. Using last year’s attendance and disciplinary records, the district wants a quantitative cost–benefit and risk analysis comparing (a) status quo detention and (b) the new program, including expected changes in absenteeism, disciplinary incidents, nurse visits, and parental opt-out rates, with sensitivity analysis for different participation levels. The school board needs a single recommendation on whether to launch a 12-month pilot, what consent/notice and data-retention terms to adopt, and what minimum clinical screening and emergency protocols are required before implementation.",232,227,459,226,223,0.003584
2025-12-13T17:58:41,145,resp_01a64513b82cd63800693d2ac191fc8195b447572861970615,gpt-5.2,"[Origin Task]:  
A U.S.-based logistics company with 2,400 employees operating in California and Texas is considering rolling out an AI-driven wearable program that continuously tracks heart rate variability, sleep, and activity to flag fatigue-related safety risks and automatically refer “high-risk” workers to telehealth clinicians contracted by the company. The COO needs to decide whether to make participation mandatory for forklift operators and long-haul drivers, while also offering premium discounts to participants, and must ensure compliance with HIPAA (where applicable), ADA accommodations, state privacy laws (including the California Consumer Privacy Act/CPRA), and employment/labor rules around medical exams, discrimination, and retaliatory actions. Using the company’s past 24 months of incident data (injury rates, near-miss frequency, workers’ comp costs, turnover) and vendor performance claims (sensitivity/specificity of fatigue detection, false-positive rates), quantify expected reductions in incidents and net financial impact under mandatory vs voluntary adoption, including costs of devices, telehealth visits, paid time for screenings, and potential legal exposure. Incorporate clinical considerations (medical appropriateness of fatigue risk thresholds, triage safety, and potential harms from over-referral or missed events) to assess whether the program meets reasonable occupational health standards. Provide a recommendation on whether and how to implement the program (mandatory vs voluntary, incentive design, data minimization/retention, and governance controls) that is legally defensible, medically responsible, and economically justified.",232,303,535,226,299,0.004648
2025-12-13T17:58:48,146,resp_0ca8a351154650e500693d2ac917ac8198a5b935c7e1b2e574,gpt-5.2,"[Origin Task]:
A mid-sized U.S. employer (700 employees across California and Texas) wants to implement a voluntary, onsite cardiometabolic screening program (blood pressure, HbA1c fingerstick, lipid panel, BMI) run by a third-party clinic, with a $30/month premium discount for participants and automatic referral to telehealth coaching for “at-risk” results. The HR team needs to ensure the program design complies with ADA and GINA limits on wellness incentives, HIPAA privacy/security rules for handling PHI, and California-specific privacy requirements, while the medical director must determine clinically appropriate cutoff thresholds and follow-up protocols that minimize harm and avoid practicing medicine without proper licensure in each state. Finance has asked for a quantitative business case estimating annual program cost, expected participation, false-positive/false-negative rates for HbA1c screening at the chosen threshold, downstream follow-up visit/lab costs, and projected savings from reduced diabetes-related claims using the company’s de-identified historical claims summary. Produce a recommendation on whether to launch, modify, or cancel the program and specify the compliant incentive structure, data-handling model, clinical criteria, and the ROI range under best/base/worst-case assumptions.",232,247,479,226,243,0.003864
2025-12-13T17:58:54,147,resp_0514344e58167a2200693d2acea32881989eef6ac6d30f22c8,gpt-5.2,"[Origin Task]:
A U.S.-based chain of assisted-living facilities wants to deploy an AI-driven medication management program that uses wearable vitals (heart rate, SpO₂, fall detection), EHR medication lists, and pharmacy refill data to trigger nurse outreach and potential dosage reviews for residents with heart failure and diabetes. After a pilot, the vendor claims a 22% reduction in hospitalizations, but the facilities’ compliance officer is concerned about HIPAA/42 CFR Part 2 data-sharing boundaries, state nurse-practice and medication-administration rules, and whether the system’s automated alerts could be considered clinical decision support that changes regulatory obligations. Using the pilot’s de-identified aggregate outcomes (baseline hospitalization rate 0.35 admissions/resident-month across 1,200 residents; pilot rate 0.27 over 4 months; average all-cause hospitalization cost $18,500; program cost $42/resident-month plus $180,000 one-time integration; false-alert rate 9% causing ~12 minutes of nurse time each; nurse fully loaded cost $52/hour), assess whether scaling to all 6,500 residents is financially justified within 12 months while maintaining clinically appropriate care pathways and legal compliance. Provide a recommendation on whether to scale, modify, or halt the rollout, including the minimum policy/contractual safeguards and clinical governance requirements needed to proceed.",232,281,513,226,277,0.00434
2025-12-13T17:58:59,148,resp_074f8e73dd2cb5af00693d2ad417d4819b954fe14ec6c7789a,gpt-5.2,"[Origin Task]:
A U.S.-based regional hospital system is considering launching an AI-assisted medication reconciliation program in its emergency departments that uses patient-reported data plus EHR history to flag potential drug–drug interactions and recommend dose adjustments for high-risk patients (elderly, renal impairment, anticoagulants). Leadership needs to decide whether to deploy it across 6 hospitals now or run a 9‑month pilot at 2 hospitals, while ensuring compliance with HIPAA, relevant state privacy laws, and FDA guidance on clinical decision support, and managing malpractice exposure if a clinician follows or ignores the tool’s suggestions. Using last year’s ED volume (420,000 visits), baseline adverse drug event rate (1.8 per 1,000 visits), average direct cost per ADE ($14,500), expected tool effect (25% relative ADE reduction with sensitivity 0.82/specificity 0.90), implementation costs ($3.2M upfront + $110k/month), and estimated added clinician time (45 seconds per flagged case; 9% of visits flagged; clinician cost $180/hour), quantify the net financial impact under both rollout options and identify the legally compliant governance/consent and documentation approach needed to minimize regulatory and liability risk. Prepare a recommendation to the hospital board on which option to pursue and the required policy controls to proceed.",232,275,507,226,271,0.004256
2025-12-13T17:59:06,149,resp_0a7506797956a59f00693d2adaa6fc8194b77c9a29fc818120,gpt-5.2,"[Origin Task]:  
A U.S.-based university is planning a one-day indoor orientation event for 1,200 attendees (900 students aged 18–24 and 300 staff aged 30–65) and wants to decide whether to require proof of MMR vaccination or offer on-site MMR vaccination, after two confirmed measles cases were reported in the county last week. The university’s general counsel needs an assessment of what vaccination and medical-exemption policy is legally permissible under state immunization rules, ADA accommodations, and privacy constraints (e.g., handling and storing vaccination records), while the campus health director needs an estimate of expected measles cases under each policy using reasonable assumptions for measles transmission, vaccine effectiveness, current estimated immunity rates, and the event’s contact patterns. The CFO also needs a quantitative comparison of costs (vaccination clinic staffing and supplies, record verification, potential refunds/cancellations, isolation/quarantine logistics, and expected medical costs) and operational impacts, including how many doses and staff hours would be required if on-site vaccination is offered and what residual outbreak risk remains if proof is required instead. Produce a recommendation memo selecting a policy and detailing the key legal constraints, the medical risk estimates, and the quantitative cost/risk trade-offs that justify the decision.",232,261,493,226,257,0.00406